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Abstract 
BACKGROUND. Previous studies have provided a rationale for understanding the 
health benefits of Mediterranean Diet (MD) against a variety of chronic diseases.  
OBJECTIVES AND EVIDENCE ANALYZED. We have used new data from the 
IMPROVE Study -a multicenter, longitudinal, observational study, carried out in 
five European countries- and fresh information from the RISMED, a study carried 
out in our Institution in subjects with a recent history of coronary revascularization 
to address: 1) the relationship between MD adherence and carotid intima-media 
thickness (c-IMT) progression; 2) whether such relationship is similar in 
populations with different nutritional patterns, and 3) whether the relationship 
between MD, baseline carotid IMT, and clinical events involves changes in 
inflammation, oxidative stress, and fatty acid [FA] composition. 
FINDINGS. In the analysis of the IMPROVE Study we have found: 1) a significant 
negative trend between most of the c-IMT-progression variables and a new 
relatively simple food frequency questionnaire to evaluate a Mediterranean-like 
dietary pattern (MLPD) score, validated a priori vs VEs in different European 
Countries; 2) that the significant association between MLDP adherence and VEs is 
independent of baseline c-IMT and c-IMT progression, and 3) that MLDP score 
adherence is associated to changes both in inflammatory markers and white blood 
cells counts. Information from the RISMED Study documented that: 1) MD 
adherence significantly affects indices of inflammation and oxidative stress 
balance; 2) blood FA profile is an index of the quality of food intake which might 
be used to estimate diet quality and compliance with nutritional advices; 3) it is 
possible to favorably modify patients’ plasma FA profiles by consuming a MD, and 
4) a relationship exists between inflammatory markers/oxidative stress status and 
modifications of the blood FA pattern.  
CONCLUSIONS AND RELEVANCE. MD adherence is key to reduce oxidative stress, 
inflammation and VEs in subjects at risk of cardiovascular events. Since common 
approaches that simultaneously target old and new risk factors for cardiovascular 
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disease enhance cardio-protection and longevity, the need for evaluating MD as a 
strategy for a better health at older ages should be explored thoroughly. 
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Riassunto. 
STATO DELL’ARTE. Studi precedenti hanno fornito una spiegazione degli effetti 
benefici della dieta mediterranea (MD) nei confronti di varie malattie croniche. 
OBIETTIVI E DATI ANALIZZATI. Abbiamo utilizzato nuovi dati dallo studio IMPROVE 
- uno studio multicentrico, longitudinale e osservazionale, svolto in cinque paesi 
europei - e informazioni preliminari dal RISMED, uno studio condotto presso il 
nostro Istituto in soggetti con una recente storia di rivascolarizzazione coronarica 
per valutare : 1) la correlazione: aderenza ad una MD e progressione dello 
spessore medio-intimale della carotide (c-IMT); 2) se tale correlazione sia simile in 
popolazioni con differenti modelli nutrizionali, e 3) se la relazione tra MD, c-IMT al 
basale ed eventi clinici (VEs), si accompagni a cambiamenti negli indici di 
infiammazione, di stress ossidativo e di composizione ematica in acidi grassi [FA]. 
RISULTATI. Dalle nuove analisi dello studio IMPROVE è emerso: 1) un significativo 
trend negativo di associazione tra la maggior parte delle variabili di progressione 
del c-IMT e il punteggio derivante da un nuovo score nutrizionale (MLPD), 
generato da un questionario relativamente semplice di frequenza di assunzione di 
7 alimenti tipici di una dieta mediterranea. Tale score è stato in precedenza 
validato contro l’insorgenza di eventi vascolari (VEs) nelle diverse popolazioni 
europee coinvolte nello studio IMPROVE; 2) che l'associazione significativa tra 
l’aderenza allo score MLDP e i VEs è indipendente dalla progressione del c-IMT e 
dal c-IMT al basale, e 3) che l’aderenza allo score MLDP è associata a cambiamenti 
sia nei marcatori di infiammazione che nella conta dei globuli bianchi. I risultati 
dello studio RISMED documentarono che: 1) l'aderenza alla DM influenza in 
maniera significativa gli indici di infiammazione e di stress ossidativo; 2) che il 
profilo dei FA del sangue è un indice della qualità del cibo assunto e che tale indice 
può servire a stimare la qualità degli alimenti ingeriti e la conformità dei pazienti ai 
consigli nutrizionali; 3) che il consumo di una DM può modificare favorevolmente il 
profilo in FA del plasma dei pazienti, e 4) che esiste una correlazione tra marcatori 
dello stato infiammatorio e di stress ossidativo e modifiche del pattern di FA. 
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CONCLUSIONI E RILEVANZA. In soggetti a rischio di eventi cardiovascolari, 
l'adesione ad una MD è fondamentale per ridurre lo stress ossidativo, 
l'infiammazione e gli VEs. Poiché gli approcci che contemporaneamente 
modificano vecchi e nuovi fattori di rischio per la malattia cardiovascolare 
aumentano la protezione cardiaca e la longevità, occorre esplorare in modo 
approfondito la MD come strategia per una migliore salute nell’anziano.  
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Introduction 
In 2013, UNESCO recognized the Mediterranean Diet (MD) as an “Intangible 
Cultural Heritage of Italy, Portugal, Spain, Morocco, Greece, Cyprus and Croatia”. 
Despite different habits in the area, common characteristics prevail in the dietary 
patterns in the Mediterranean basin: high consumption of olive oil, legumes, 
unrefined cereals, fruits, and vegetables, moderate/high fish consumption, 
moderate consumption of dairy products (mostly as cheese and yogurt), moderate 
wine consumption (especially during meals), and low consumption of meat and 
meat products. Olive oil –that has a central position in all such dietary patterns-, is 
important not only for its own health benefits, but also because it is often 
consumed with large quantities of vegetables in the form of salads and large 
quantities of legumes in the form of cooked foods. In addition to olive oil and 
olives, other essential components of the MD are wheat, grapes, and their 
derivatives (Figure 1). The Italian variant of MD is characterized by high pasta 
consumption, whereas fish consumption is particularly high in Spain. 1, 2 Total fat 
content is generally ≥40% (Greece), or ≥30% (Italy) of total energy intake. 1 
However, the monounsaturated to saturated fats ratio of MD in Southern 
European countries is much higher than in other regions of the world, including 
northern Europe and North America. Thus, it is appropriate to consider these 
patterns as variants of a single entity, and to define MD as a modern dietary 
approach inspired by the traditional diets of the countries bordering the 
Mediterranean Sea. 3  
 
Figure 1 Mediterranean Diet: geographical distribution and major components  
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Historically, it might be convenient to define MD as the dietary pattern in the 
olive-growing areas of the Mediterranean regions in the late 1950s and early 
1960s, when the consequences of World War II were over and the fast-food 
culture had not yet invaded the basin.1  
 
History 
In the Greek medical tradition, first ‘rational’ medical treatises were written in the 
fifth century BC by a series of authors associated with Hippocrates and his thought 
over a period of more than 150 years. In the thought of the Hippocratic doctors, 
food was absorbed into the body to be broken down into nutritional substances to 
sustain the body and to guarantee the body's heat. How these products acted 
within the body, however, was not clear.  
In his adaptation of the Hippocratic system, Galen (second century AD) extended 
and refined the Hippocratic system and identified nutrition, drug therapy and 
surgery as three branches of medicine. Accordingly, many doctors, including Galen 
wrote cookery books.4 Galen wrote extensive treatises on nutrition, and clarified 
that diet might also have drug-based outcomes. Whether and to what extent diet 
was an integral entity or the sum of identifiable components (e.g., olive oil, fruits, 
vegetables) to be evaluated separately, or whether the beneficial effects of a diet 
(e.g. the MD) or of its major components were reproduced in different 
populations (e.g. in people living far from the Mediterranean region) was not 
addressed by Galen.1  
 
Ancel Keys’ initiative.  
Ancel Keys developed the concept that, at the population level, "rich" diets might 
be linked to higher plasma cholesterol and to a higher than normal tendency to 
coronary artery disease (CAD).5 This observation was pursued during his long-stay 
in Italy (Pioppi), where he highlighted that the rate of ischemic heart disease was 
lower in Mediterranean regions. 
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This was tested in the "Seven Countries Study", a longitudinal survey of population 
samples from Finland, Greece, Italy, Japan, The Netherlands, U.S. and Yugoslavia, 
with at least 5-year follow-up. Medical records; ECGs at rest and after exercise, 
and a blood sample were obtained from population-based men 40-59 years old. 
The basic concept of a 3-way relationship between dietary lipids, serum 
cholesterol, and CAD emerged from the results of the Seven Countries Study6, 7. In 
cross-population analyses, 10-yr coronary mortality rate was strongly related to 
average dietary saturated fatty acid intake. Higher values were found in Finnish, 
Dutch, and American samples, intermediate intake levels in the Mediterranean 
population samples, and low values in Japanese men. Similar findings were found 
for serum cholesterol: the highest the sample average cholesterol level, the 
highest the coronary mortality rate. In addition, dietary saturated fatty acids were 
closely related to serum cholesterol. Overall, these data argued for serum 
cholesterol as a major CAD risk factor, and for the need of a population-wide 
prevention of epidemic cardiovascular (CV) disease (CVD)8. 
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Studies supporting Ancel Keys’ observation 
The Lyon Diet Heart Study is a prospective, randomized single-blinded secondary 
prevention multicenter trial -death and nonfatal AMI being its primary endpoints-, 
designed to test the hypothesis that a MD enriched with α-linoleic acid (ALA) 
might improve the prognosis of survivors of a first acute myocardial infarction 
(AMI).9-12 Of the 600 survivors enlisted, half adopted a prudential diet and as many 
adopted a Mediterranean-type of diet, with no more butter, cream and 
delicatessen (which were replaced by poultry); less meat (beef, lamb, pork), and 
more bread, more cereals, more legumes and beans, more fresh vegetables and 
fruits, more fish, and more olive oil. Olive oil was recommended for salad and food 
preparations. For subjects who did not like it, olive oil was replaced by an 
experimental canola oil-based margarine (erucid acid free rapeseed oil). All dietary 
instructions were detailed and customized to each patient.9-12 This strategy was 
well accepted by the patients who, at the end of the trial, were still following 
dietary patterns superimposable to those of the protocol.9-12 
The whole protocol stemmed from the lowest rates in the world of cardiovascular 
diseases (and of vascular complications in patients with established CAD) in 
populations either following a MD or a diet low in n-6 fatty acids and rich in n-3 
fatty acids (a major component of fish and fish oil).9-12 In addition to a low n-6/ n-3 
fatty acid ratio, and to the high oleic acid intake (and the low saturated fat intake) 
of the traditional MD, patients were instructed to lower animal fat consumption 
and to use vegetable oils such as olive oil (that does not contain ALA) and/or 
canola oil (that contains ALA and moderate amounts of LA). 12 The experimental 
MD tested in the trial supplied less than 30% of energy from fats and less than 8% 
of energy from saturated fats. As to essential fatty acids, the intake of LA, the main 
n-6 fatty acid, was restricted to 4% of energy and the intake of ALA, the main n-3 
fatty acid, made up more than 0.6% of energy.13  
The subjects were followed up for 5 years starting 6 months after the ischemic 
event.  
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At the 2-year follow-up, there were 16 CV deaths in the control group and 3 in the 
experimental one. After correction for other factors, a surprisingly high (76%) 
reduction in the risk of cardiac death was found during the observation period.12 
Consistent with the protective effect of the diet, a striking 50 to 70% reduction of 
the risk of recurrence was reported after four years of follow-up.9-12 Such 
reduction was associated with enhanced plasma levels of eicosapentaenoic acid 
(EPA) and its parent fatty acid, ALA. In keeping with this, plasma arachidonic acid 
(the fatty acid precursor of the 2 series of prostaglandins and thromboxane), was 
significantly (p<0.005) reduced in subjects who had received the experimental 
diet. In addition, vitamin E, which has been previously reported to reduce the risk 
of CAD14, was significantly (p<0.005) increased while granulocyte count was 
lowered. On the other hand, high-normal white cells counts have been related 
with cerebral thrombosis and re-infarction, maximal association being found with 
granulocyte counts. 15-17 The involvement of white cells in blood rheology, 
endothelial cell injury (free radical generation), and blood coagulation (generation 
of tissue factor) provides a biological plausibility for this association. Thus, 
mechanisms other than polyunsaturated fatty acids changes should be considered 
in the cardio-protective effects of this diet.18-20 
 
European Prospective Investigation into Cancer and Nutrition (EPIC). This is an 
ongoing multi-center prospective cohort study designed to investigate the 
relationship between nutrition and cancer, with the potential for studying other 
diseases.21 EPIC is the largest single resource available today world-wide for 
prospective investigations on the etiology of cancers (and other diseases) that can 
integrate questionnaire data on lifestyle and diet, biomarkers of diet and of 
endogenous metabolism (e.g. hormones and growth factors) and genetic 
polymorphisms.21 The study currently includes 519, 978 participants (366, 521 
women and 153, 457 men, mostly aged 35–70 years) in 23 centers located in 10 
European countries, to be followed for cancer incidence and cause-specific 
mortality for several decades. At enrolment, which took place between 1992 and 
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2000 at each of the different centers, information addressing usual diet was 
collected through a dietary questionnaire and information on lifestyle variables 
through a non-dietary questionnaire. Anthropometric measurements were 
performed and blood samples taken; plasma, serum, red cells and buffy coat 
fractions were separated and aliquoted were stored mostly in liquid nitrogen for 
long-term evaluations.21 The usual dietary intake during the year preceding 
enrollment was assessed with the use of a semi-quantitative validated food-
frequency questionnaire including approximately 150 commonly consumed foods 
and beverages and the questionnaire was administered by specially trained 
interviewers.22, 23 For each of the items, individuals were asked to report their 
frequency of consumption and portion size, the latter being calculated based on 
information provided on household units and 76 photographs of usual portion 
sizes. Standard portion sizes were used for the estimation of consumed quantities, 
23 and nutrient intakes were calculated by means of a food-composition data base 
modified to accommodate dietary specificities of individual Countries.24 
Eventually, 14 all-inclusive food groups or nutrients were considered: meat, fish, 
eggs, dairy products, potatoes, vegetables, legumes, fruits and nuts, cereals, sugar 
and sweets, nonalcoholic beverages, saturated lipids and margarines, and 
monounsaturated (mainly olive oil), and polyunsaturated lipids (vegetable-seed 
oils). For each participant, intake (g/day) of each of the indicated groups and total 
energy intake were calculated.22 To calibrate dietary measurements, a 
standardized, computer-assisted 24-hour dietary recall was implemented at each 
center on stratified random samples of the participants, for a total of 36,900 
subjects.  
On 22,043 Greek adults from the Greek cohort, Trichopoulou et al. carried out an 
observational prospective study to investigate the capacity of a 10-point scale 
Mediterranean (MD) score to predict the overall and CAD mortality. During a 
median of 44 months of follow-up, there were 275 deaths. A high adherence to 
the MD was associated with a lower total mortality (adjusted hazard ratio [HR] for 
death associated with a two-point increment in the MD score, 0.75 [95 % 
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confidence interval [CI], 0.64 to 0.87]). An inverse association with high adherence 
to MD diet was true for both death due to CAD (HR, 0.67 [95% CI, 0.47 to 0.94]) 
and death due to cancer (HR, 0.76 [95% CI, 0.59 to 0.98]).a The association with 
the MD score appeared to be slightly stronger for mortality from CAD than for 
mortality from cancer, although mortality from cancer was reduced significantly. 
The inverse association between the Mediterranean-diet score and total mortality 
was independent of sex, body-mass index (BMI), waist-to-hip ratio, smoking, level 
of education and of physical activity. In analyses stratified according to age, the 
relation between the MD score and mortality was significant among participants 
55 years of age or older but not among participants younger than 55 years of age 
(P=0.34).24 In analyses adjusted for age, sex, BMI, smoking habits, waist to-hip 
ratio, energy-expenditure score, total energy intake, and years of education, the 
only individual measures that were predictive of total mortality were the intake of 
fruits and nuts and the ratio of monounsaturated/saturated lipids.  
 
PREDIMED Study was a multicenter nutritional primary prevention randomized 
clinical trial (RCT) carried out in Spain between 2003 and 2011 which tested the 
long-term effects of the MD on incident CVD in men and women at high CVD risk 
(but no history of previous CVD episodes at enrolment) aged 55-75 years (men) or 
60- 80 years (women). Participants were selected from >200 primary care facilities 
affiliated with 11 recruiting sites. The presence of either type 2 diabetes mellitus 
(T2DM) or ≥3 risk factors (smoking, overweight or obesity, hypertension/HTN, 
dyslipidemia/DLP, and family history of early-onset CVD) were major criteria for 
recruitment. Participants were randomized into one of three diets: 1) MD 
supplemented with extra-virgin olive oil (EVOO); 2) MD supplemented with nuts; 
and 3) control diet (advice on a low-fat diet). Trained dietitians delivered the 
intervention. Throughout the study, participants attended individual visits and 
group sessions in which they were instructed to follow their diets. Participants also 
                                                          
a An example of dietary changes resulting in such an increment would be a substantial increase in 
the intake of monounsaturated lipids relative to saturated lipids and a substantial reduction in the 
intake of meat. 
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attended quarterly group sessions where they received written material with 
information on key Mediterranean foods and seasonal shopping lists, menus and 
specific recipes for a typical week. of EVOO (1 L per week, including a minimum of 
50 mL/day for participants and the rest for family needs) or mixed nuts (30 g/day: 
15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts plus extra allocations for the 
family) were supplied at no cost to each participant randomly assigned to the MD 
groups on a quarterly basis during the group sessions with dietitians. Participants 
in the control diet group attended similar quarterly sessions with explanations and 
written material on the low-fat diet and they received non-food gifts in these 
sessions. The three diets were energy-unrestricted and no intervention on physical 
activity was carried out. Validated food frequency questionnaires covering 137 
foods were collected yearly by the dietitians. 25 Fasting blood and spot urine were 
obtained and serum, plasma and DNA samples were stored. Urinary hydroxytirosol 
and plasma ALA measurements were determined in random sub-samples and 
were employed as objective biomarkers of adherence to EVOO and walnut 
consumption, respectively. The pre-specified primary end-point of the trial was 
incident CVD (a composite of non-fatal myocardial infarction/MI, non-fatal stroke 
or CVD death). The trial was neither powered nor designed to independently 
assess each of the three components of the combined end-point. Secondary 
outcomes included total mortality, T2DM, metabolic syndrome (MetS), peripheral 
arterial disease (PAD), atrial fibrillation (AF), neurodegenerative diseases and 
major cancers. An event adjudication committee, whose members were blinded to 
group allocation, was responsible for event ascertainment. As many as 7,447 
participants were randomized into the three intervention groups that were well 
balanced with respect to their baseline characteristics and pharmacologic 
treatments. The mean age of participants was 67 years, 57% were women and the 
mean body mass index was 30 kg/m2. The baseline prevalence of diabetes was 
nearly 50% and the prevalence of DLP and HTN was higher than 70% and 80%, 
respectively. Compliance with the intervention in the two MD groups was 
adequate.26 There were no between-group differences in physical activity during 
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the study. The effect of baseline adherence to the 14-point score with respect to 
the subsequent incidence of the primary CVD end-point during follow-up was 
assessed.27 The multivariable-adjusted HR for participants with a baseline 14-item 
screener in the 2nd-3rd quintile who scored between 8-9 points was 0.72 (95% CI: 
0.55-0.94), and for those with the highest adherence (two upper quintiles, scoring 
10-14 points), it was 0.47 (CI: 0.35-0.65). The observed rates per 1,000 person-
years for the primary end-point were 8.1, 8.0, and 11.2 in the MD+EVOO, 
MD+nuts, and control groups, respectively. The unadjusted HRs were 0.70 (CI, 
0.53-0.91) for the MD+EVOO and 0.70 (CI, 0.53-0.94) for the MD+nuts. The pre-
specified primary end-point of the trial occurred in 288 participants during a 
median follow-up of 4.8 years. No effect on all-cause mortality was apparent. 
Significant disease risk reductions were observed for incident T2DM (in the subset 
of participants initially free of T2DM) 28, 29 and for other CVD outcomes, such as 
PAD30 and AF31. In comparison with the control group, participants randomized to 
either MD were more likely to show reversion of MetS, with HR 1.35 (CI 1.15–1.58) 
for the MD+EVOO, and HR 1.28 (CI 1.08–1.51) for the MD+nuts. Similarly, the MD 
interventions reduced blood pressure (BP) and the risk of HTN32, 33, and slowed the 
progression of subclinical atherosclerosis, as determined by changes in 
ultrasound-assessed carotid intima-media thickness (c-IMT) and plaque 
measurements.34, 35 
 
MD scores 
The need to measure dietary intake without error, propose food frequency 
questionnaires (FFQs) as the gold-standard technique to reach this goal being FFQs 
low-cost and easy-to-use tools.36, 37 Traditionally, they are used to describe 
habitual dietary intake, particularly in epidemiologic studies. However, in the last 
10 years, they were also used to stratify patients according to their healthy dietary 
habit and, moreover to better characterize they risk to develop different 
pathology (e.g. cancer, CVD). Among them 2 are the most widely used and 
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accepted FFQs: European Prospective Investigation into Cancer and Nutrition 
(EPIC)24 and the Prevención con Dieta Mediterránea (PREDIMED).38 
EPIC Score. The Mediterranean food pattern of EPIC score was evaluated by 
developing an a priori 10-point score. 24, 39 A value of 0 or 1 was assigned to each 
of nine components, with the sex-specific medians used as the cut-off points. For 
beneficial components (vegetables, legumes, fruits and nuts, cereal, and fish), 
persons whose consumption was below the median were assigned a value of 0, 
and all others were assigned a value of 1. For detrimental components (meat and 
dairy products), persons whose consumption was below the median were 
assigned a value of 1, and all others were assigned a value of 0. A value of 1 was 
given to men consuming 10–<50 g of alcohol per day and to women consuming 5–
25 g. For lipid intake, the ratio of monounsaturated fatty acids [MUFAs] to 
saturated fatty acids [SFA] was calculated. Those above the sex-specific median in 
the MUFA/SFA ratio were given 1 point. Thus, the total Mediterranean diet score 
ranged from 0 (minimal adherence to the traditional MD) to 9 (maximal 
adherence) 
  
PREDIMED Score. The PREDIMED SCORE is a validated 14-point MD screener 40 
used by dietitians as a tool to both assess actual adherence to the MD and 
enhance future adherence. These 14 items are:  
1. Use of olive oil as the main culinary fat  
2. Consumption of ≥4 tablespoons/d of olive oil (including oil used 
for frying, salads, out-of-house meals, etc.)  
3. Consumption of ≥ 2 servings/d of vegetables  
4. Consumption of ≥ 3 servings/d of fruits  
5. Consumption of <1 serving/d of red meat, hamburger or meat 
products (ham, sausage, etc.)  
6. Consumption of <1 serving/d of butter, margarine, or cream  
7. Consumption of <1 serving/d of sweetened and/or carbonated 
beverages  
19 
 
8. Consumption of ≥1 serving/d of wine  
9. Consumption of ≥ 3 servings/week of legumes  
10. Consumption of ≥ 3 servings/week of fish or shellfish  
11. Consumption of <3 servings/week of commercial sweets or 
pastries (not homemade), such as cakes, cookies, biscuits or custard  
12. Consumption of ≥ 3 servings/week of nuts (including peanuts)  
13. Preferential consumption of chicken, turkey or rabbit meat 
instead of veal, pork, hamburger or sausage  
14. Consumption of ≥ 2 servings/week of sofrito, a sauce made with 
tomato and onion, leek or garlic and simmered with olive oil.  
Dietitians collected yearly food frequency questionnaires covering 137 foods.41  
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The protective role of the individual components of the MD: current evidence. 
Biochemical, clinical, and epidemiologic research during the last 15 years has 
provided a rationale for the health benefits of the MD against a wide range of 
chronic diseases. 42, 43 Although the responsible compounds/mechanisms of such 
protection have not been established, an inverse relation of vegetables and fruits 
consumption with cancer having been shown in Italy, France, Spain, and Greece.44-
51 Four recently reviewed epidemiologic studies52, 53 show that olive oil conveys 
some form of protection against breast cancer, and limited data suggest that olive 
oil may reduce the risk of endometrial and ovarian cancer.46, 54 Vitamin E, which 
exists in abundance in olive oil, is associated with a statistically significant 
decrease in the risk of sporadic colorectal cancer in carriers of wild-type ki-ras 
genotype.55 Moreover, an olive oil compound, 2-(3,4-dihydroxyphenyl) ethanol 
(DPE), is a potent specific inhibitor of lipoxygenase activities.56 MD is associated 
with high intakes of Ca2+ Mg2+ and K1+, which exert major beneficial effects on a 
wide range of physiologic processes.57 Moderate daily consumption of wine during 
meals is a characteristic of the MD.58 Moderate drinking of alcoholic beverages 
reduces the risk of CAD probably by increasing levels of serum high-density 
lipoprotein (HDL) cholesterol. The latter levels are probably as important for the 
prevention of CAD as low levels of serum low-density lipoprotein (LDL) and total 
cholesterol.59, 60 Moreover, monounsaturated fat, including olive oil, increases HDL 
cholesterol more than does polyunsaturated fat61 and carbohydrates 61-63making it 
an optimal energy-generating nutrient.42, 43 Olive oil and complex carbohydrates 
derived from legumes, whole-wheat bread, and cereals, prevent/modulate 
postprandial hyperglycemia, which could be important in MetS. Finally, 
consumption of olive oil-derived monounsaturated fat may increase bone mineral 
density thus reducing the risk of osteoporosis.3 Details of individual components of 
the MD will be provided below. 
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Single food components 
 
Fats. Both the AHA/ACC and ESC guidelines strongly endorse replacing saturated 
and trans-fatty acids with monounsaturated and polyunsaturated fats for both 
primary and secondary prevention.64, 65 In addition to recent RCT data, 38 early 
meta-analyses primarily evaluating the effects of fatty acids on surrogate markers 
of CV disease, indicated that MUFA intake increases lipid levels, including HDL.66 A 
large meta-analysis suggests an inverse correlation between blood pressure and 
MUFAs intake.67 The cardioprotective effects of olive oil are accounted for by the 
presence of its phenolic compounds obtained from the water-soluble fraction and 
include mostly the low-molecular-weight molecule hydroxytyrosol and oleuropein, 
which are both potent antioxidants, free radical scavengers, and enzyme 
modulators.68 Two randomized, blinded crossover trials have assessed the 
antioxidant effect of dietary supplementation of extra virgin olive oil in humans: 
EUROLIVE69 and the Virgin Olive Oil Study (VOLOS).70 The Italian VOLOS trial 70 
studied the inflammatory protective potential of olive oil in 22 mildly dyslipidemic 
patients. After a 7-week treatment period, no change in overall serum lipid 
profiles were found. In contrast, total antioxidant capacity of plasma and 
circulating levels of serum thromboxane B2 (an index of maximal platelet 
activation) were both reduced by the administration of olive oil. In the Effect of 
Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study, 69 a 
randomized, crossover controlled trial performed at 6 research centers across 5 
European Countries, patients received olive oil with low, medium, or high phenolic 
content for 3 weeks, with intervening 2-week washout periods. Markers of 
oxidative stress, (e.g. conjugated dienes, hydroxy fatty acids, and circulating 
oxidized LDL) linearly decreased with increasing phenolic content of the diet. In 
contrast to butter and walnut-rich meals, no effect of olive oil-rich meal does not 
influence postprandial activation of NF (nuclear factor)-kB pathway in monocytes 
of healthy volunteers,71 thus arguing for an anti-inflammatory effect of olive oil. 
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Finally, some data indicate a beneficial effect of olive oil supplementation on 
endothelial function in low- to moderate-risk patients.72 In keeping with this, a 
randomized crossover trial in a small group of healthy patients showed MD (rich 
with olive oil) improves endothelial function; reduces systemic inflammation and 
lowers the endothelial progenitor cell numbers, a marker of increased endothelial 
repair.73  
Fruits and Vegetables. The ESC 64 and the AHA 65 strongly endorse the use of fruits 
and vegetables to reduce CV disease risk. In addition, the AHA has strongly 
recommended the intake of a variety of phytochemicals very abundant in fruits 
and vegetables.74 These recommendations are based upon a broad base of 
observational studies, and subsequent meta-analyses. Although the results were 
slightly skewed by heterogeneity and publication bias, a meta-analysis of nearly 
200,000 patients showed a 4% relative risk reduction in CV disease with each 
serving of vegetables, with a 7% relative risk reduction in CV disease with each 
daily increase in servings of fruit.75 Another large (over 200,000 patients) meta-
analysis of observational studies showed a 17% reduction in CV disease events 
with 3-5 servings of fruits and vegetables daily as the primary endpoint.76  
A 3.0-mm Hg decrease in systolic blood pressure among women (with no 
difference in men) who consumed a higher amount of fruits, vegetables, or 
vitamin C has been reported.77 A cross-sectional analysis of the SUN prospective 
cohort 78 showed that fruit and vegetable consumption is inversely associated with 
blood pressure in a Mediterranean population with a high vegetable-fat intake. 
Increased fruit and vegetable intake has also been linked with a low BMI in a 
cross-sectional study.79 Finally, the prospective Chicago Western Electric Study 
showed a slight benefit on blood pressure, over a 7-year period of time, in middle-
aged men with an increased fruit and vegetable intake compared with those with 
a higher red meat intake.80 Population-based evidence from the EPIC-Heart study 
showed, after an 8-year follow up of 313,074 patients without overt 
atherosclerosis, a 22% lower risk of coronary death in those consuming 8 portions 
of fruits and vegetables a day, as compared with 3 portions or less.81 RCT data only 
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address the CV disease benefits of fruits and vegetables by using CV disease 
surrogates as endpoints. A 2001 RCT showed a strong trend for increased fruits 
and vegetables consumption as to lowering in lipid or blood pressure profiles.82 A 
subsequent RCT showed a significant effect of fruit and vegetable consumption on 
both plasma antioxidant concentrations and blood pressure.83 In addition to the 
evidence relating the antioxidant properties 84 and the health benefits of an high 
flavonol intake,85 effects on nitric oxide (NO) species and/or on weight loss are 
also associated with the beneficial effects of diets high in fruits and vegetables 86.  
 
Whole Grain. The AHA guidelines indicate that diets high in fiber (e.g. whole 
grains, oats, and barley), reduce CV disease morbidity and mortality through lipid 
lowering, and recommend a total dietary fiber intake of 25-30 g per day from 
whole foods.87 Likewise, the ESC endorses intake of foods high in dietary fiber to 
promote CV disease health.64 RCTs show data on surrogate markers of CV disease 
such as blood pressure, cholesterol, and markers of inflammation. However, no 
information is available on hard CV disease endpoints. A small RCT showed 
beneficial effects on BMI and waist circumference in the group randomized to 
hypocaloric whole grains as compared to that receiving hypocaloric refined 
grains.88 Cholesterol level lowering, the group obtaining all carbohydrates from 
12-week whole grains had a significant improvement in C-reactive protein (CRP). A 
larger, subsequent, RCT confirmed these results in 230 participants randomized to 
3 daily servings of whole grains ± whole oats vs refined carbohydrates, the former 
serving exhibiting a significant reduction in blood pressure and lipid profiles.89 
However, in over 300 overweight individuals in whom normal carbohydrate intake 
was randomly replaced with control, intermediate whole grain, or high whole 
grain diets for 4 months, no significant differences in surrogate markers of CV 
were observed after 4 months.90 In spite of this, a 21% reduction in CV events and 
mortality in prospective cohort studies has been documented in a meta-analysis 
devoted to whole grains merits.91 Larger observational studies such as the Iowa 
Women’s Study and the Nurse Health Study92, 93 show a reduction in CV disease 
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morbidity with increased intake of whole grain sources. Finally, observational data 
show improved all-cause and CV disease mortality in women with T2DM who 
consume whole grains.94 Mechanisms 95 of the benefit of whole grains on CV 
disease include reduced inflammation, lower reactive oxidation species generation 
and improved antioxidant capabilities.96 High-fiber whole grain diets inhibit 
absorption of fats, simple carbohydrates, or toxins. improved lipid profiles, and 
improved blood pressure control,97 and improved glucose metabolism98, 99, and 
weight loss 100 have also been reported. Yet the recommendation promoting 
whole grains has no RCT data behind it to show a reduction in CV disease 
morbidity or mortality. As such, increased whole grain intake for CV disease 
prevention should be pursued in the frame of a MD to maximize its 
cardioprotective potential.  
 
Nuts. An early evaluation of observational studies showed that replacing walnuts, 
peanuts, almonds, or other nuts for a serving of carbohydrates or saturated fats 
reduced blood lipids as well as the risk for CV disease by 30% and 45%, 
respectively.101, 102 Almost 10 years later, it has been argued that nut consumption 
leads to a 0.67 risk reduction on CV disease.103 Furthermore, a 2009 meta-analysis 
showed a significant reduction in LDL cholesterol, inflammatory and oxidants 
mediators with increased walnut consumption,104 without any evidence of 
reduction in risk factors or CV disease mortality. A more recent meta-analysis, 
however, pointed out benefits of nuts105 on weight loss. A meta-analysis of 4 
observational studies, showed an inverse relationship between nut consumption 
and CV disease (primary endpoint), and documented ≈40% decrease in the 
incidence of primary CV disease with consumption of at least 4 nut servings per 
week and up to 10% reduction with a single serving per week.106 Due to the small 
sample size of the studies and the large variety of nuts studied, old RCT data are 
less convincing with respect to this issue. Recent RCT data provide evidence that 
the MD supplemented with nuts provides primary CV disease-prevention 
benefits.38 Being these benefits seen in the frame of a MD, it would be 
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inappropriate to ascribe the benefit solely to nuts. In keeping with their ability to 
improving CV morbidity and mortality, several cohort studies and few small RCTs 
have shown a benefit of nuts as to improving lipid profiles and reducing blood 
pressure and reactive oxygen species (ROS) generation, and improving vascular 
function. Such evidence on CV disease prevention argues for increased nut 
consumption as being able per se to provide CV benefits, greater benefits being 
observed when added to the MD.107  
 
Legumes. Legumes, the seeds of plants that contain roots which use nitrogen-
fixing bacteria, are considered a low-glycemic useful dietary source of protein and 
fiber. Initial observational studies showed legume and soy intake to be beneficial 
to prevent CV disease (11% reduction in CV disease in women who consumed 
legumes 4 or more times weekly over those who consumed legumes one or fewer 
times weekly).108 Similar observational data have been reported in Japan109 and 
China.110 However, RCT data seldom address hard CV disease endpoints, and the 
grouped data show only marginal benefits as to lipid levels, blood pressure, or 
endothelial function. Small RCTs in low- to moderate-risk patients show little 
change in lipid levels 111 112, 113. On the other hand, one meta-analysis shows a 5% 
reduction in LDL levels in patients randomized to high legume intake,114 
documenting that this reduction had no effect on hard CV disease endpoints. RCTs 
have shown a benefit on blood pressure in patients with moderate 
hypertension.115 In keeping with this, a large sample of RCTs studies116 and an 
earlier meta-analysis117 show no benefit from soy supplementation on 
normotensive patients. Consistent with prior meta-analyses114 a recent RCT shows 
no benefit of soy on NO bioavailability and BP in moderately hypertensive, 
postmenopausal women.118 However, subsequent meta-analyses have challenged 
this statement. Due to a potential anti-inflammatory and vaso-protective benefit, 
studies has examined the effect of soy on endothelial function. A recent meta-
analysis of RCTs shows no benefit of soy on endothelial function,119 a moderate 
benefit of soy supplementation being only documented when age-related results 
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are adjusted for baseline endothelial function. Thus, presently there is little direct 
evidence that legume intake alone has direct CV disease benefits. It should thus be 
hypothesized that legume intake must be part of the MD, and cannot be 
supplemented in isolation for CV disease protection.  
 
Plants and polyphenols. An international panel of experts reviewed the effects of 
a moderate consumption of beer on human health has been carried out by.120 
Low-moderate (up to 1 drink per day in women, up to 2 in men), non-bingeing 
beer consumption, reduces the risk of CV disease. This effect is comparable to that 
of wine, at similar alcohol amounts. Moderate consumption of either beer 
or wine may confer greater CV protection than spirits. Although specific data on 
beer are inconclusive, observational studies indicate that low-moderate alcohol 
consumption is associated with a reduced risk of developing neurodegenerative 
disease. There is no evidence that beer drinking differs from other alcoholic 
beverages as to the risk of some cancers. Besides the obvious exceptions (people 
engaged in actions that require concentration, skill or coordination; children; 
adolescents; pregnant women, individuals at risk for alcoholism, and those with 
cardiomyopathy, cardiac arrhythmias, depression, and/or liver/pancreatic 
diseases), evidence suggests a J-shaped relationship between alcohol consumption 
and all-cause mortality, lower risks for moderate alcohol consumers than for 
abstainers (or heavy drinkers) being found. 120  
Studies in model organisms (e.g., C. elegans, D. melanogaster), and in laboratory 
rodents suggest that red wine constituents (e.g., resveratrol) may positively affect 
both health and lifespan.121, 122 In a mouse model, resveratrol activates 
transcriptional factor Nrf2 and lowers oxidative stress, hence protecting the 
endothelium 123 and inhibiting inflammation in macrophages (by downregulating 
the proinflammatory NF𝜅B expression).124 Resveratrol induces Sirt1 125-127, and it is 
conceivable that the endothelium protection and NF𝜅B inhibition appears to be 
connected to Sirt1 expression. Olive oil phenols induce proteosomal activity and 
Sirt1 signalling. 128, 129 The role of polyphenols in gene regulation via sirtuins and 
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transcription factors Nrf2 and NF𝜅B is now clear.130 Quercetin (a polyphenol found 
in onions) also induces Sirt1.127 Mice consuming diets rich in olive oil phenolics 
(e.g., hydroxytyrosol) exhibit decreased oxidative damage markers (e.g., lipid 
peroxides, protein carbonyls) and improved expression of Nrf2-dependent genes 
encoding antioxidant (𝛾GCS, NQO1) and cardioprotective proteins (e.g. 
paraoxonase).  
 
n-3 Polyunsaturated fatty acids. The theory that eating fish, a major component 
of the MD may protect against cardiac death was first derived from the results of a 
secondary prevention trial, the Diet And Reinfarction Trial (DART), which showed a 
significant ≈30% reduction both in total and CV mortality in patients who 
consumed at least two servings of fatty fish per week.131 The authors suggested 
that the protective effect of fish might result from a preventive effect on 
ventricular fibrillation (VF), since no benefit was observed on the incidence of non-
fatal AMI. The hypothesis was consistent with the evidence that the very-long-
chain n-3 fatty acids, the dominant fatty acids in fish oil and fatty fish, have major 
effects on the occurrence of VF in the setting of myocardial ischemia/reperfusion 
in several animal models.132 In dogs, using an in vivo model of sudden cardiac 
death (SCD), Billman et al showed a marked reduction of VF after intravenous 
administration of pure n-3 fatty acids, including the very-long-chain fatty acids 
present in fish oil and ALA.133  
A second aspect of the involvement of n-3 fatty acids in SCD is related to their role 
in the metabolism of eicosanoids. In competition with n-6 fatty acids, precursors 
of prostaglandins and thromboxane with potent pro-aggregatory and vaso-
constrictive effects, n-3 fatty acids are the precursors of a broad array of 
structurally diverse and potent bioactive lipids (including eicosanoids, 
prostaglandins and thromboxane), which play a major role in the prevention of VF 
during myocardial ischemia/reperfusion.134 Suppression (≥70%) of ventricular 
premature complexes in middle-aged patients with frequent ventricular extra 
systoles randomly assigned to take either fish oil or placebo has been 
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documented.135 Survivors of AMI136 and healthy men137 improved their 
measurements of heart rate variability while receiving fish oil. This is in keeping 
with the fact that parasympathetic cardiac tone provides protection against VF.138 
Epidemiological studies support the hypothesis of a clinically significant 
antiarrhythmic effect of n-3 fatty acids in secondary prevention of CAD.139 In a 
large prospective study (more than 20 000 participants with a follow-up of 11 
years), Albert et al found that the risk of SCD was 50% lower in men who 
consumed fish at least once a week than in those who had fish less than once a 
month.140 In that study, the main protective effect of fish consumption (or of very-
long-chain n-3 fatty acids) was related to a reduction of arrhythmia. In a double 
blind trial in patients with implantable cardiac defibrillator, Leaf reported a 40% 
reduction of recurrent ventricular arrhythmias following fish oil capsules141, but 
this hypothesis was challenged142 Presently, there is no clear explanation for that 
discrepancy between these two trials. Dietary confounders (e.g. saturated fatty 
acid intake; background marine/plant n-3 vs n-6 fatty acid intake, trans fatty acid 
intake) which could interfere with the n-3 fatty acids given with the capsules, were 
not measured in these trials nor were they included for adjustments in the 
calculations of the risks. The GISSI-Prevenzione trial addressed the question of the 
health benefits of vitamin E and very-long-chain n-3 fatty acids (EPA+ DHA). 
Patients (n = 11,324) surviving a recent AMI (≈3 months) were randomly assigned 
to supplements of n-3 fatty acids (1 g daily), vitamin E (300mg daily), both or none 
(control) for 3.5 years. The primary efficacy endpoint was the combination of 
death and non-fatal AMI and stroke. Secondary analyses included overall 
mortality, CV mortality and SCD. Treatment with n-3 fatty acids significantly 
lowered the risk of the primary endpoint (15% decrease of the relative risk). 
Overall mortality was reduced by 20% and CV mortality by 30%. However, the 
effect on SCD (45% lower) accounted for most of the benefits seen in the primary 
combined endpoint and both overall and CV mortality. There was no difference 
across the treatment groups for non-fatal CV events, a result comparable to that 
of DART.131 Two central questions remain to be addressed with respect to these 
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data. 1) In the GISSI- Prevenzione trial, all patients were advised (before 
randomization) to follow a MD type of diet after their AMI. In their report, the 
GISSI investigators confirmed that the patients of both groups actually did so, > 
80% of them reporting daily olive oil consumption.143 Whether such patients 
would have been protected while consuming a non-MD is unknown so far. 
However, similar to the Lyon Diet Heart Study, 9, 12 pooling together the 
randomized groups and adjusting for age, sex, smoking, concomitant drug therapy 
and randomized treatment, the GISSI investigators found that the higher the MD 
adherence (as evaluated by an MD score) the lower the risk of dying (from any 
cause), a 50% difference in such risk being found between the best and the worst 
MD adherence.144 2) Unpublished data (the European IMMIDIET Project) suggest 
that compared with British (South of London) and Belgian (Flemish) populations, 
the Italian population is relatively deficient in n-3 fatty acids. It is not sure whether 
the results with such a low dose of n-3 fatty acids would have been similar in 
populations with higher intakes in n-6 and trans fatty acids. 
Al in all, large case-control studies and prospective intervention trials consistently 
showed that dietary and non-dietary intake of ω-3 fatty acids directly or indirectly 
affects cardiac electrophysiology and that n-3 fatty acids supplementation lowers 
AMI and SCD in patients with CAD. 145.146-148 However, experimental data also 
suggest newer directions to be pursued in the area, the anti-atherogeneic and 
anti-inflammatory properties of n-3 FA having been largely investigated in in vitro, 
animal and human studies. Cellular models of early atherogenesis based on 
cultured endothelial cells challenged with various pro-atherogenic stimuli show 
that both DHA and EPA significantly affect major critical events leading to 
endothelial activation, including the expression of VCAM-1. Such regulatory effects 
occur in a range of DHA concentrations compatible with nutritional 
supplementation to a normal Western diet and are strictly related in magnitude to 
the extent of incorporation into total cell lipids.149-151 In addition to the expression 
of transmembrane molecules involved in leukocyte recruitment, effects of DHA 
and EPA also involve the pro-inflammatory and chemoattractant soluble proteins 
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IL-6,152 IL-8,151 macrophage-colony stimulating factor (M-CSF),153 and monocyte 
chemoattractant protein (MCP)-1.154 Such effects are associated by reduced 
monocyte adhesion to cytokine-activated endothelium.150, 151 An antioxidant effect 
can also be documented in cultured endothelial cells supplemented with DHA.153, 
155, 156 A reduced membrane assembly and activation of the ROS-producing 
enzyme complex NADPH-oxidase, has been reported as a likely consequence of 
plasma membrane changes occurring upon DHA incorporation.155 On the other 
hand, when supplemented to macrophages in culture, EPA and DHA significantly 
reduce the stimulated release of MMPs,154, 157 thus likely contributing to plaque-
stabilizing effects of PUFA in humans.158 In addition, fish oils prevent serotonin-
induced smooth muscle cells proliferation,159 an effect that is involved in 
preventing restenosis after endovascular interventions.  
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Clinical Vascular Diseases 
Athrothrombosis. 
Atherothrombosis -the substrate of the large majority of complications of 
atherosclerosis leading to clinical vascular disease and the leading cause of death 
worldwide,160- is an unpredictable, sudden rupture or erosion/fissure of the 
atherosclerotic plaque,161 leading to platelet activation and thrombus formation in 
the vessels.162 Thrombus formation is a dynamic process in which platelets 
aggregate but also spontaneously disaggregate, leading to embolization of platelet 
aggregates from an evolving thrombus.163 In the case of an occlusive thrombus, 
depending on the localization of the atherosclerotic plaque, there will be an acute 
ischemic event in the coronary, cerebral or peripheral vascular territory, 
potentially leading to permanent tissue damage. In the case of a non-occlusive 
thrombus, ischemic symptoms are temporary. Occlusive thrombosis in 
atherosclerotic coronary arteries may give rise to major clinical events such as 
AMI, cardiac death and acute coronary syndrome (ACS). Atherothrombosis of the 
cerebral arteries may result in transient ischemic attacks (TIAs) or ischemic stroke. 
In the peripheral arteries, thrombosis superimposed on atherosclerotic plaques 
contributes to the progression of peripheral arterial disease (PAD), producing 
intermittent claudication (leg pain on walking that is relieved by rest); ischemic 
necrosis and, potentially, loss of the limb. Hence, the same underlying vascular 
process cause ACS, TIA, stroke, and PAD.164 Because of the generalized nature of 
atherosclerosis, symptoms in one vascular bed, for example, AMI, are highly 
predictive of risk of further ischemic atherothrombotic events elsewhere.165  
Cardiovascular Disease (CVD) 
CVD, the major complication of atherothrombosis, is the number one cause of 
death worldwide, with yearly deaths expected to increase from 17.3 to 23.6 
million by 2030.166 Today CV deaths accounts for approximately 1/3 of all deaths 
globally. Medical expenses and medication costs associated with the treatment of 
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CVD are huge, totalling $126 billion in 2010 in the US. 167 The attention devoted to 
the CVD is due to the rapid increment of CV deaths during the last decades (12.5% 
increment).168 In reality, in the 2005/2015 decade there was a 15.6% reduction of 
age-specific deaths.169-171 However, this was relevant in High-income countries 
(HICs) than in Middle-income countries (MICs) and Low-income countries (LICs).170, 
172 Accordingly, the vast majority of CVD deaths now occur in LICs and MICs.  
In 2013, the World Health Organization, launched the “25x25 Global Action Plan”, 
a project aimed at reducing the mortality by 25% by 2025. This project focuses on 
correction of 4 mains health-related behaviors: tobacco use, diet, physical activity, 
and alcohol.173 The occurrence of CVD is multifactorial and major risk factors are 
T2DM, hypertension, smoking habit, overweight, and dyslipidemia. Early 
recognition and treatment of patients at high risk of atherosclerosis is a major goal 
to reduce the incidence of atherothrombotic events and CV disease. 
Ischemic Heart Disease 
IHD is the leading component of the CVD burden. Both the prevalence and the 
mortality of IHD increase dramatically with age.169 During the past 25 years, both 
the incidence and mortality (age standardized) have decreased globally, the 
greatest decline being found in HICs.174, 175 Age-standardized mortality also 
remains high in South Asia, North Africa, and the Middle East.169 On the other 
hand, the large increases documented during the 1990s in Eastern Europe and 
Central Asia are now reversing.169, 174 Years of life lost because of IHD are highest 
in South Asia, mostly reflecting early onset of IHD. 174, 175  
Congestive Heart Failure  
Congestive Heart Failure (CHF) due to ischemic heart disease (IHD), hypertensive 
heart disease, or cardiomyopathy/ myocarditis contributes significantly to disease 
burden.169 Both the prevalence of CHF and the associated mortality increase with 
age.169 Despite advances in CHF management during the past 3 decades, data 
from HICs suggest that 5-year survival after the diagnosis of CHF is still only 50-
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60%, mortality rates being substantially higher in LICs and MICs.176, 177Population 
based studies in North America and Europe estimate a prevalence of CHF of 1% to 
2%, with 80% of new cases occurring in those >65 years of age.176, 178 Limited data 
from Asia suggest that the prevalence of CHF may range there between 1% and 
7%. However such estimates predominantly rely on either single-center or hospital 
based studies, which may not truly reflect community rates.179  
Atrial Fibrillation 
Atrial fibrillation (AF) is the sixth leading cause of CVD-related mortality and the 
eighth leading cause of disability among CV conditions.168, 169 The prevalence of AF 
increases dramatically in older age groups as does the associated mortality.169 The 
age-adjusted prevalence and incidence of AF have increased during the past 
decades.180 The highest prevalence of AF has been reported in North America and 
the lowest in the Asia-Pacific region.180 However, these data also may not be 
reliable because few large community-based studies have examined AF 
epidemiology outside of Western countries, and methods used to detect AF vary.  
Rheumatic Heart Disease 
Rheumatic heart disease (RHD) is the fifth leading cause of CVD-related mortality 
and ranks sixth in disability from CV conditions. The disease burden is 
concentrated in poor countries, where overcrowding and reduced access to care 
coexist with an inadequate management of valvular disease.169 Current estimates 
suggest that the highest prevalence of RHD now occur in countries of Oceania, 
South Asia, South East Asia, Central Asia, Sub-Saharan Africa, parts of the Middle 
East, and in the Caribbean.181 Since 1990, the prevalence of RHD appears to have 
increased in these endemic regions while incident acute rheumatic fever has 
decreased.182 Although these differing trends may be related to longer survival of 
patients with RHD, this may also be the result of more RHD cases being identified 
earlier with wider use of echocardiography.181 
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Cerebrovascular disease 
Stroke is the second leading contributor to CVD disease burden. The prevalence of 
stroke increases with age, peaking in those between 74 and 79 years of age.169 
Stroke-related mortality also increases with age.169 Approximately 63% of ischemic 
and 80% of hemorrhagic stroke now occur in LICs and MICs. Ischemic stroke is 
more common than hemorrhagic stroke although hemorrhagic stroke is associated 
with higher mortality and contributes more to disability.183, 184 On average, 
populations in MICs and LICs suffer strokes 6 years younger than in HICs.185 
Countries with the highest age-standardized prevalence of stroke currently are in 
Oceania, Eastern Europe, Central Asia, and South- East Asia while mortality from 
stoke is highest in Oceania and Sub-Saharan Africa.169, 185 
In a world of magnetic resonance imaging the historical definition of TIA as “a 
transient episode of neurological dysfunction caused by focal brain, spinal cord, or 
retinal ischemia without acute infarction”187 lasting less than 24 hours is no longer 
appropriate. Although most patients are asymptomatic at presentation and have 
normal physical examination, 188 the incidence of acute ischemic stroke within 48 
hours of an emergency visit for TIA is 4.8% (182/3,814 patients; 95% CI 4.0% to 
5.6%).189 Secondary stroke prevention—the rapid implementation of multiple 
interventions—reduces the outcome of stroke by 80%.190-193 Because accurate 
diagnosis, rapid testing, and implementation of treatments can prevent disabling 
and fatal strokes, TIA has enormous public health importance.188  
Subarachnoid hemorrhage  
Subarachnoid hemorrhage accounts for 5 to 10% of all strokes in the United 
States,194 and affected patients tend to be younger than those affected by other 
subtypes of stroke, which results in a greater loss of productive life.195 
Subarachnoid hemorrhage without a preceding trauma is due to an intracranial 
aneurysm rupture in 80% of cases. Among the patients with aneurysmal 
subarachnoid hemorrhage who survive, half suffer long-term neuropsychological 
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effects and decreased quality of life.196 Early identification and treatment of the 
aneurysm can prevent aneurysm re-rupture and address sequelae from the initial 
rupture. Intervention may be appropriate in cases of subarachnoid hemorrhage 
that are not caused by aneurysms (e.g., cases involving arteriovenous 
malformation), but up to 10% of cases of non-aneurysmal subarachnoid 
hemorrhage involve no vascular abnormality, and surgical or endovascular 
treatment is not necessary.197 
Peripheral vascular disease 
PAD affects more than 5% of population older than 60.198 In the US, PAD affects 
about 8 – 10 million Americans, and every year it causes 500,000 hospitalizations 
and 100,000 angiograms.199 Significant CAD (in at least one coronary artery) has 
been documented in 60% – 80% of patients with PAD, and hemodynamically 
significant carotid artery stenosis (by duplex ultrasound) has been found in 12% – 
25% of cases.200 The risk of AMI is increased by 20% – 60%, whereas the risk of 
coronary death is increased 2 – 6-fold in PAD patients.160 For this reason, early 
diagnosis of PAD may help identify patients at risk for CV events.201 PAD is 
associated with a 40% increase in the risk of stroke, and PAD severity is positively 
associated with the incidence of TIAs and stroke.199 The clinical spectrum of PAD is 
widely variable: patients may either be asymptomatic or have pain as a result of a 
minimal walking.202 Most asymptomatic patients with PAD will be identified 
through ankle-brachial index (ABI) screening.203 ABI (i.e. the ratio of the highest 
systolic blood pressure in the lower limb to that of the arm) is an easy, reliable 
means for evaluating PAD severity.204 PAD with intermittent claudication (IC) is 
often undiagnosed and, in turn, undertreated. The low percentage of diagnosis (∼ 
30%) among those with a PAD is of concern because of the high risk of adverse 
outcomes related to the worsening of PAD. 205-207 Among those with ABI 0.9, ∼ 
25% will experience worsening claudication necessitating surgical repair or 
amputation. In a 10-year follow-up 208, about 55% of PAD (ABI 0.9) patients died of 
CV disease, 10% of cerebrovascular disease, and 25% of non-vascular reasons. Less 
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than 10% died of other vascular events (mostly, aortic aneurysms in the 
abdomen). In another follow-up209, 10-year mortality was 61.8% in males with 
symptomatic PAD (ABI 0.9); in comparison, in males without PAD (ABI 0.9) 
mortality was 16.9%. Mortality rates in females were 33.3% and 11.6%, 
respectively. Less than 25% of patients with PAD (ABI 0.9) survived for 10 y, 
vascular mortality being the dominant cause of death in that setting. After 
correction for established risk factors, PAD severity was an independent predictor 
of death.  
Critical limb ischemia (CLI; ABI 0.4), is observed in 12% of the PAD population.210 In 
most cases, CLI is an advanced thrombotic complication of PAD, due to inadequate 
resting blood flow to the lower limbs, and is marked by rest pain, ulceration, and 
eventually gangrene and loss of the limb.211 CLI is seldom the result of an acute 
event (e.g. embolism, thrombosis, or trauma). Patients with CLI are candidates for 
prompt revascularization. CLI increases mortality: in the first year after the 
diagnosis 25% of patients (45% with amputation) will die, and 30% of them will 
have amputations, whereas only 45% will survive with both legs. After 5 years 
more than 60% of patients have died. 212 
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Subclinical Vascular Diseases: Methods of Detection 
Carotid Intima media thickness (c-IMT)  
c-IMT assessment is a non-invasive imaging test for subclinical atherosclerosis.213, 
214 This test has been widely accepted as one of the strongest predictors of major 
CV events (stroke, AMI, CHF, CV death).215, 216 The presence of carotid plaques is 
an even more reliable predictor of CV events than c-IMT.217 Thus, this surrogate 
marker of subclinical atherosclerosis provides important prognostic information 
over and above traditional CV risk factors. 
High resolution B-Mode Eco-tomography  
B-Mode ultrasonography is a non-invasive technique that allows to study subclinical 
atherosclerosis of the major surface vascular districts. Morphological information 
relating both to the lumen and the blood vessel are achieved by using this 
technique. High Resolution B-Mode Eco-tomography uses high frequency 
ultrasound (7-13 Mhz) and provides real-time bi-dimensional images of the major 
unshielded surfaces of blood vessels. This technique also provides detailed 
information on the size and characteristics of early small injuries of the wall.218-222 
B-Mode ultrasonography shows a great sensitivity, specificity, accuracy and 
reproducibility.223 It is cheaper than invasive techniques and allows for carefully 
performing studies on the evolution of atherosclerosis and the effect of treatments. 
Limits of B-Mode Eco-tomography include: the inability to display anechogenous 
structures (e.g. lipid areas) or structures with blood-like acoustic impedance 
(hemorrhage inside a plaque or recent thrombotic occlusions).224 Eco-colordoppler 
and angiography should be preferred when measuring calcific stenosis.  
Ultrasound anatomy of carotid arteries 
In a typical ultrasonographic image, the common carotid, the carotid bifurcation 
and the internal and external carotid arteries are easily detectable (Figure 2). In 
ultrasonographic images, the beginning of the dilation of the bifurcation is the distal 
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limit of the common carotid and is recognized by the presence of a medium-
intensive physiological thickening, the "bifurcation crest/peak". The bifurcation, 
separates the internal carotid, -which discharges the frontal parts of the brain and 
the vision organs-, and the external carotid that disrupts the neck, face, and cranial 
walls. The Carotid bifurcation has two key anatomical reference points that allow it 
to be identified. The lower margin of the carotid bifurcation is defined by the 
proximal part of the bifurcation dilation, the upper limit is given by the so-called 
"flow-divider", which separates the origin of the internal and external arteries. The 
internal carotid is delimited proximally by the flow-divider and differs from the 
outer carotid for the larger caliber and for the origin with a typically bulbous 
morphology. The branch of the thyroid artery from the outer carotid artery further 
differentiates the two arteries.225  
 
Figure 2. Carotid Bifurcation 
 
Thickness of the intramammary complex (or extracranial carotids IMT)  
IMT of the extracranial carotids is the most important parameter that can be 
evaluated using B-Mode ultrasonography. The anatomical correspondence 
between the ultrasonic image and the intimal average complex has been 
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documented more than 30 years ago220 in a study where a real estimate of the mean 
intimal thickness was obtain by measuring the distance between the "blood-intima" 
and "media-adventitia" interfaces of the abdominal aorta and of common carotid 
arteries. This method is now standardized and is used as a reference standard for 
studying carotid atherosclerosis and for evaluating CV risk. The major benefit of the 
c-IMT analysis is that it allows the evaluation of individual subjects to develop early 
atherosclerotic disease, before the occurrence of atherosclerotic lesions (plaques).  
In addition to being an index of local atherosclerosis,226, 227 c-IMT also predicts 
similar lesions in other districts e.g. the coronary vasculature.215, 223, 228-232 c-IMT is 
also directly related with major risk factors for atherosclerosis.74, 233-236 Current 
epidemiological data indicate that ≥1 mm c-IMT increase in asymptomatic adults is 
a risk factor for AMI and/or cerebrovascular disease.237 c-IMT thus provides a 
comprehensive view of over time injuries on the arterial wall due to risk factors, 237 
and has been proposed to be included in algorithms for refining CV risk estimates215, 
238 The predictive value of c-IMT is further strengthened by the identification of 
high-risk patients for cardio- and cerebro-vascular events.215, 239 Accordingly, this 
technique is currently employed in clinical and research centers to assist physicians 
to prescribe pharmacological treatment in primary prevention in patients at high CV 
risk.240  
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MD and subclinical disease 
MD and c-IMT  
Few epidemiological studies have addressed the relationships between MD and c-
IMT. 34, 35, 241, 242 Two studies have investigated the relationship between MD and 
c-IMT progression in cohorts of children or elderly individuals, 242-245 and a single 
interventional study, carried out in a Mediterranean population (PREDIMED), has 
addressed the effect of MD on c-IMT progression. To date there are no large 
observational studies addressing the relationship between MD adherence and c-
IMT progression in populations from different European countries with different 
nutritional patterns/habits.  
In view of its capacity to predict incident coronary events, c-IMT has been 
proposed as a surrogate marker of coronary atherosclerosis. 213, 246 Analysis of 
baseline data of the IMPROVE study has identified latitude as the strongest 
independent determinant of c-IMT. 247 The association between latitude and 
carotid atherosclerosis profile remained statistically significant over and above 
traditional and new vascular risk factors (VRFs) and baseline Framingham risk 
score (FRS). 248, 249 In addition, a significant association between c-IMT and c-IMT 
progression and future vascular events has been shown in the IMPROVE study. 247, 
249 
MD and Carotid Plaques 
The association between MD adherence and carotid plaque thickness and area 
was first evaluated in an observational study that included 1,374 participants of 
the population-based Northern Manhattan Study (60% female, 60% Hispanic, 18% 
White, 19% Black, mean age 66 ± 9 years).250 c-IMT and plaque were measured 
using B-mode ultrasound. A MD adherence score (range = 0–9, 9 representing 
maximal adherence) was employed as a continuous variable and as quintiles 
(3/4/5/6 –9 vs. 0–2). There was no association between MD and c-IMT or plaque 
presence. MD adherence was inversely associated with the 75th percentile of 
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plaque thickness and median of plaque area in quantile regression analyses. These 
associations persisted after controlling for demographics, smoking habit, physical 
activity, and total energy consumption (effect of a 1-point increase in MD score on 
the 75th percentile of plaque thickness = −0.049 mm, p = 0.03; median of plaque 
area = −0.371 mm2, p = 0.03), and when also controlling for vascular disease 
biomarkers, medication use, BMI, and previous cardiac disease. The protective 
associations were strongest for a MD score of 5 (4th quintile) vs. 0–2 (bottom 
quintile). Differential effects of a MD on plaque thickness and area across 
race/ethnic groups was suggested.250 In the same cohort, no association with 
clinical stroke was found. However, larger studies have found an association of 
MD with clinical stroke251 and associations of MD with imaging biomarkers of 
cerebrovascular damage.252, 253 Studies have also shown that the top quartile of 
carotid plaque area (vs. the lowest quartile) is associated with a 3–4-fold increased 
risk of stroke, AMI or death.254, 255 Accordingly, plaque area may be a better 
measure of atherosclerosis than plaque thickness,254-257 plaques progressing along 
the carotid artery 2–3 times faster than for thickening.258 Despite the relationship 
between carotid plaque burden and risk of clinical events, few studies have 
examined the role of vascular risk factors in relation to this novel marker of 
disease risk. Likewise, whether the association between MD and carotid plaque 
burden is consistent with a dose–response relationship or a threshold effect is 
unknown so far.  
MD and Vascular Stiffness 
Whether adherence to the MD, obesity, and BP are related to indices of AS has 
been evaluated in childhood. Two hundred and seventy-seven children aged 12 
years were measured with the R6.5 Pulsecor® monitor, which performs 
measurements using an upper arm BP cuff held at above systolic pressure for a 
short time.259 Of such children, 43% were overweight or obese. The AI in the 
brachial artery, the peripheral pulse pressure to central pulse pressure (PPP/CPP) 
ratio, and the reflected wave transit time to height ratio were used as indices of 
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AS. The degree of adherence to the MD was assessed by the KIDMED index, which 
includes 16 questions on specific dietary habits. In multivariate regression models, 
the KIDMED index had a negative correlation with AI (β=-0.114; p=0.026) ant this 
relation was independent of obesity. In contrast, indices of AS were related to 
mean peripheral BP (β=0.110; p=0.063), heart rate (β=-0.508; p=0.000), and height 
(β=-0.370; p=0.000), while BMI had an independent correlation to PPP/CPP (β=-
0.182; p=0.039).259 
Information in adults only pertain to acute postprandial conditions in subjects 
simultaneously receiving wine and olive oil.260 Fifteen healthy subjects consumed 
four standard meals on different days, containing 50 g of olive oil and 250 ml of 
wine, in a randomized cross-over study design. Two types of wine [red (R) and 
white (W)] and two types of olive oil [green (G) and refined (O) (rich and poor in 
antioxidants, respectively)] were used in all possible combinations. Applanation 
tonometry and aortic pulse wave analysis were performed when fasting and 1, 2 
and 3 hours post-prandially. A second group of 15 healthy individuals matched for 
age, gender and body mass index served as controls. All meals decreased AIx (RO 
and RG, P<0.001; WO, PU0.007; and WG, PU0.039). The AIx reduction after RG, 
RO, WO and WG was significantly different from the AIx response of the control 
group. No difference was observed in the reduction of AIx between sessions, but a 
significantly earlier peak decrease in AIx, as well as a prolonged decreasing effect, 
was observed after RG and RO consumption compared to WO and WG. Central 
systolic and diastolic pressure were diminished after all four combinations of wine 
and olive oil (P<0.05), an information consistent with the concept that a combined 
consumption of wine and olive oil provides beneficial postprandial effects on 
hemodynamics. 260 
MD and FMD. 
The relationship between diet and endothelial dysfunction has been examined in 
epidemiological and interventional studies. The prospective cohort Nurse's Health 
Study compared endothelial function as related to two dietary patterns261: a food 
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pattern characterized by a high intake of fruits, vegetables, whole grains, fish and 
poultry, and a Western food pattern characterized by higher intake of red meat, 
processed meat, refined cereals and fries. Regardless of risk factors such as 
smoking and age, and after controlling for body weight, women who consumed a 
"prudent" diet had significantly lower levels of E-selectin -a biological marker of 
endothelial dysfunction-, than women who they consumed a Western diet. 
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MD and Conventional Vascular Risk Factors for CAD  
Blood pressure 
The Dietary Approaches to Stop Hypertension (DASH) clinical trial18 enrolled 459 
adults with systolic BPs of <160 mm Hg and diastolic BPs 80–95 mm Hg. Initially, 
the subjects were fed a control diet that was low in fruits, vegetables, and dairy 
products, and a diet that has a fat content typical of the average US diet. Then 
they were randomly assigned to receive: 1) the control diet; 2) a diet rich in fruits 
and vegetables; or 3) a “combination” diet rich in fruits, vegetables, and low-fat 
dairy products with reduced saturated and total fat. The “combination” diet was 
associated with 5.5 mm Hg and 3.0 mm Hg lower systolic and diastolic BPs, 
respectively, than the control diet (p<0.001), while the fruits-and vegetables diet 
reduced systolic BP by 2.8 mm Hg more (p<0.001) than the control diet. Among 
the 133 subjects with hypertension, the combination diet reduced systolic and 
diastolic BP by 11.4 mm Hg and 5.5 mm Hg more, respectively, than the control 
diet (p<0.001 for each). Among the 326 subjects without hypertension, the 
corresponding reductions were 3.5 mm Hg (p<0.001) and 2.1 mm Hg (p=0.003).18 
These findings argue for not limiting to single nutrients the focus of dietary 
changes for BP control. Blood pressure variability (BPV) is a novel risk factor for 
CVD. It is unknown whether dietary pattern plays a role in modulating BPV.262 As 
many as 274 consecutive patients with stable CAD were followed-up. The MD 
score (MDS) was derived for all individuals upon recruitment, blood pressure (BP) 
was measured during each subsequent clinic visit and the visit-to-visit BPV was 
calculated. The occurrence of major adverse CV events (MACEs) and all-cause 
mortality were monitored. After a mean follow-up of 77 ± 12 months, 16.1% of the 
study population developed MACEs. About 11.3% died from all causes. Patients 
who developed MACEs or all-cause mortality had a greater systolic BPV compared 
to those who did not develop an adverse event. Patients who developed a MACE 
had a lower MDS and further analysis revealed those who developed a stroke had 
a lower MDS compared with those who did not, but there were no significant 
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differences in MDS between CAD patients with or without subsequent acute 
coronary syndrome, CV, or all-cause mortality. After adjusting for confounding 
variables, a high MDS was an independent predictor for low systolic BPV (B −0.74, 
95% confidence interval −1.27 to −0.21, P < 0.01) and was protective against a 
subsequent stroke (hazards ratio 0.48, 95% confidence interval 0.24 to 0.94, P = 
0.03).262 
Physical activity 
It is known that the age-dependent decline in endothelial and microvascular 
integrity may be reversed when combining an 8-week exercise with an MD 
intervention. Whether the risk-reduction improvement in microcirculatory and 
cardiorespiratory functions are sustained in this age-group after a 1-year follow-up 
has been also investigated.263 Twenty sedentary healthy participants (age, 55 ± 4 
years) underwent cardiopulmonary exercise tolerance test and were assessed for 
their upper- and lower-limb vascular endothelial cutaneous vascular conductance 
(CVC) using laser Doppler fluximetry (LDF) with endothelium-dependent [ACh 
(acetylcholine chloride)] and endothelium-independent [sodium nitroprusside] 
vasodilation, 1 year after completing the intervention. With respect to ACh, 
compared to baseline, both MD and exercise groups improved their microvascular 
responses, a stronger improvement in the MD group in comparison to the exercise 
group, for ACh (p = 0.04, d = 0.41) being found. In the upper body, the time point 
and group interaction for ACh, indicated a non-statistically significant (p= 0.07, d= 
0.24) improvement for MD. Cardiorespiratory improvement in ventilatory 
threshold was maintained 1 year after (12.2 ±3.0 vs. 13.2±3.2ml ∙ kg−1 ∙ min−1, p b 
0.05). Since the original improvements were still evident, particularly in the 
microcirculatory and cardiorespiratory assessments, 1 year after the initial study, 
the data were taken to suggest that a brief intervention combining MD with 
exercise in this high-risk group is a promising long-term health benefit strategy.263 
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Glucose control  
Some studies in T2DM patients reported a positive effect of the MD on glycemic 
control, 264-269 others did not.270-272 A recent meta-analysis has addressed some of 
the unmet issues in this area.273 The control diets comprised low-fat diet, usual 
dietary habits, non-restricted calorie low-carbohydrate diet, the 2003 American 
Diabetes Association (ADA) diet and high-carbohydrate diet. Although the MD diet 
varied across studies, all the included diets comprised the basic characteristics of 
an MD diet. However, two studies compared three separate diets, one study268 
compared a MD versus two types of control diets, and the other one compared 
two versions of MD versus a control diet. Finally, two trials270, 272 used a high-
monounsaturated fatty acid-enriched intervention diet, that was comparable to 
the traditional MD. These different 11 arms were evaluated separately.273 Nine 
studies with 11 arms (n = 1,178 patients) contributed data for the change in HbA1c 
from baseline. Compared with control diets, the MD was associated with a 
significant reduction in HbA1c (mean difference, − 0.30; 95% CI, − 0.46 to − 0.14) 
by using a random effects model. Evidence of between-study heterogeneity was 
found in this analysis (I2 = 67.2%; P = 0.001). Changes in fasting plasma glucose 
(FPG) levels were pooled from six studies with seven arms (n = 580 patients). 
Subjects who consumed MD had decreased FPG levels (−0.72 mmol/l; CI, − 1.24 to 
− 0.21) compared with subjects who consumed control diets. Heterogeneity of the 
effect measures on FPG was detected (I2 = 66.1%; P = 0.007). Five studies with six 
arms (n = 531 patients) measured fasting insulin. Compared with control diets, 
there was a minimal but statistically significant decline in fasting insulin levels 
(−0.55 μU/ml; CI, − 0.81 to − 0.29) in subjects who used MD. No heterogeneity was 
observed (I2 = 0.0%; P = 0.46). As to insulin resistance, although the beneficial 
effect of MD compared with control diet was not statistically significant (mean 
difference, − 0.55; CI, − 1.53 to 0.42), the MD had greater probability on improving 
insulin resistance. Moderate heterogeneity was present between the studies (I2 = 
45.8%; P = 0.137).273 Six studies with seven arms reported changes in BMI from 
baseline. A random effects meta-analysis comprising 520 patients randomly 
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assigned to the MD and 500 assigned to the control diets were employed for this 
study. The MD was more effective in decreasing BMI compared with the control 
diets (mean difference, − 0.29 kg/m2; 95% CI, − 0.46 to − 0.12; I2 = 0.0%; P = 
0.976). As to body weight, six studies involving 835 patients showed that MD was 
associated with a significant weight loss as compared with control diets (0.29 kg; 
CI, − 0.55 to − 0.04; I2 = 0.0%; P = 0.924). In addition, compared with control diets, 
MD also significantly decreased total cholesterol (mean difference, − 0.14 mmol/l; 
95% CI, − 0.19 to − 0.09) and triglyceride (−0.29 mmol/l; CI, − 0.47 to − 0.10) 
concentrations and increased HDL-cholesterol (0.06 mmol/l; CI, 0.02 to 0.10), 
without affecting LDL cholesterol (−0.11 mmol/l; CI, − 0.24 to 0.01). There was 
moderate heterogeneity for the analyses of triglyceride (I2 = 58.0%; P = 0.03) and 
HDL (I2 = 53.6%; P = 0.04) cholesterol. Finally, a trend towards reduction in systolic 
(−1.45mmHg; CI, − 1.97 to − 0.94; I2 = 0.0%; P = 0.58) and diastolic (−1.41 mmHg; 
CI, − 1.84 to − 0.97; I2 = 0.0%; P = 0.95) blood pressure was found in the MD 
groups.273 
Total cholesterol 
The relationship between serum total cholesterol and long-term mortality from 
(CAD) in different cultures was first analyzed in the Seven Countries Study. 274 
Total cholesterol was measured at baseline and at 5- and 10-year follow-up in 
12,467 men aged 40 through 59 years in 16 cohorts located in seven countries: 
five European countries, the United States, and Japan. To increase statistical 
power six cohorts were formed, based on similarities in culture and cholesterol 
changes during the first 10 years of follow-up. The age-standardized CAD mortality 
rates in the six cohorts ranged from 3% to 20%. The RRs for the highest compared 
with the lowest cholesterol quartile ranged from 1.5 to 2.3, except for Japan (RR of 
1.1). For a cholesterol level of ≈5.45 mmol/L (210 mg/dL), CAD mortality rates 
varied from 4% to 5% in Japan and Mediterranean Southern Europe to ≈15% in 
Northern Europe. Except for Japan, the relative increase in CAD mortality due to a 
given cholesterol increase was similar in all cultures. Using a linear approximation, 
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a 0.50-mmol/L (20-mg/dL) increase in total cholesterol corresponded to an 
increase in CAD mortality risk of 12%.274 
LDL-cholesterol 
Lowering LDL-cholesterol concentration is the primary target of therapy for the 
prevention of CV disease (CVD).275-277 However, in addition to LDL-Cholesterol 
concentrations, it has been shown that a more detailed analysis of LDL physico-
chemical properties (e.g., size and oxidation) provides further insight into 
individual CV risk,278, 279 individuals with a predominance of small, dense LDL 
particles (sdLDL) being at increased risk of CAD compared to those with larger, 
buoyant LDL particles.280-282 Compared with large LDL, sdLDL possess a lower 
affinity for the LDL receptor and a longer half-life in plasma283, bind more tightly to 
arterial proteoglycans284, penetrate the arterial sub-endothelium more easily285 
and are more susceptible to oxidation.286 LDL oxidation contributes to 
atherosclerotic plaque formation by causing endothelial dysfunction, the release 
of inflammatory cytokines and macrophage transformation into foam cells.279 
Accordingly, oxidized LDL (oxLDL) concentrations have been identified as an 
important marker of atherosclerotic lesions.279, 287 Sex disparities have been 
reported for LDL physico-chemical properties, men being characterized by a higher 
proportion of sdLDL and greater concentrations of oxLDL than premenopausal 
women.288-293 A specific study was carried out to verify whether the impact of MD 
on LDL size distribution, as well as on oxLDL concentrations differs between men 
and women. It appeared that adhering to the MD, in addition to a clinically-
relevant reduction in LDL-cholesterol concentrations, has additional positive 
effects on LDL particle size phenotype, leading to a favorable redistribution from 
smaller to larger LDL in men, but not in women.294 
HDL-cholesterol 
Dietary supplementation of unsaturated FA protects against atherosclerosis and 
CV events.295 The effects of dietary FA on the lipid metabolism have been widely 
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investigated: mono- and poly-unsaturated FA (MUFA/PUFA) supplemented to the 
diet are effective in lowering total cholesterol (TC) and LDL cholesterol, while 
saturated FA (SFA) increase TC and LDL-cholesterol.61, 296 HDL cholesterol shows a 
slight decrease with PUFA dietary supplementation.61 However this concept has 
been challenged.296 Plasma levels of PUFA, but not SFA, are associated with lower 
apolipoprotein AI (apo-AI) and HDL-C levels in the Framingham study, but with 
different features in men and women.297 How plasma non-esterified fatty acids 
(NEFA) composition correlates with plasma HDL-C levels in a free living population 
of Southern Italy that follows a “modern” version of the MD with a lower content 
of fibers and an excess of introduced calories in comparison with the “traditional” 
diet has been addressed in one study.298 Olive oil constitutes the majority of 
dietary fat, in this study. The study population was characterized by a high 
prevalence of obesity298, 299 and MetS.299 On average, HDL-C levels of this 
population were slightly lower than the Italian levels.298, 299 HDL-C levels of this 
population correlated positively with the proportion of plasma PUFA and 
negatively with SFA. Among individual NEFA, HDL-C levels strongly and negatively 
correlated with C14:0, C18:1n9 and C20:1n9, and positively with C16:1. An “in 
vitro” model of cultured hepatoma cells was then conditioned with NEFA and 
those FA that best correlated with plasma HDL-C levels in the population, or that 
resulted very abundant in the plasma, as C18:0. This “in vitro” study documented 
that myristic acid modified the HDL binding to liver cultured cells. C14:0 increased 
the nonspecific binding of HDL to cell surface and it did not affect the saturable 
receptor-mediated binding. C14:0. Thus, myristic acid is negatively correlated with 
plasma levels of HDL-C in a MD characterized by an excess of obesity and MetS, 
and part of this correlation might be explained by an increase of HDL binding to 
hepatic HSPG and subsequent cholesteryl esters stripping by proteoglycans-bound 
lipases.300 
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Triglycerides 
Observational studies have found an association between elevated triglyceride 
(TG) levels and increased risk for CV disease morbidity and mortality. In the 1990s, 
the lipid research clinics follow-up study301, the physicians' health study302, and a 
meta-analysis of 17 population-based prospective studies 303 consistently found 
that increased concentrations of TGs are associated with an increased risk of AMI, 
CAD, and mortality, independent of HDL concentrations. 304-306 In recent years, a 
genetic predisposition to elevated TG levels has also been documented.307 TGs 
have also independently contribute in the causal pathway of atherosclerosis. The 
effect of the MD on TGs has been thoroughly investigated. In a 3-mo intervention, 
a MD supplemented with walnuts reduced TGs by 0.15 mmol/L compared with a 
low-fat control diet.308 One 3-mo intervention trial compared a low-fat diet and a 
MD for effects on TG-rich lipoprotein (TRL), TGs, and TRL-TGs.309 In both groups, 
TGs were 0.2 mmol/L lower after adjustment for BMI; TRL-TGs were also lower by 
0.16 mmol/L in the MD group.  
Smoking habit  
Vardavas et al.310 performed a literature search to investigate whether adherence 
to MD might have a role to modify the deleterious effects on human health of 
active and passive smoking. They found that both epidemiological and laboratory 
studies show that MD has a protective effect against biochemical and molecular 
processes that lead to cancer, CV disease and respiratory illness. Based on the high 
daily intake of vitamins and antioxidants, MD provides a variety of compounds 
that positively affect certain outcomes related to smoking. Moreover, some 
diseases attributable to smoking, such as lung cancer, asthma and CV disease, are 
inversely associated with the use of certain antioxidants and lipids.  
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Obesity  
Traditional nutritional advice for the treatment of obesity and associated disorders 
has emphasized avoiding animal fat and, preferably, all types of dietary fat, and 
replacing them with carbohydrate (CHO).311 The central arguments against animal 
fats consumption and of fatty foods in general, have been a high content in 
cholesterol-rising saturated fatty acids (SFA) and excess energy, thought to 
promote obesity. Scientific evidence has accumulated concerning the beneficial 
role of diets with a relatively high MUFA content on CV risk factor outcomes, 
including diabetes.312 The debate on what is the best nutrient to replace energy 
sources from SFA in the diet, CHO or MUFA, has indirectly been solved by the 
Women’s Health Initiative study313 in which the lack of protective effect of a high-
CHO diet against CV disease has been documented. Recent results from a 20-year 
follow-up of the prospective Nurses’ Health Study314 suggest that a low-CHO diet 
(high-fat and/or high-protein) does not promote CAD and might actually reduce its 
incidence when the diet is high in unsaturated fat and vegetable proteins. The 
results of observational studies in Mediterranean countries, where people 
complying with the MD consume significant amounts of olive oil, have shown that 
increasing adherence to such high-fat, high-MUFA dietary pattern is associated 
with decreasing obesity rates.315-317 Accordingly, a prospective study from a 
Mediterranean country has shown that increasing olive oil use is not associated 
with weight gain.318 Moreover, a recent cohort study (n=613 individuals) has 
demonstrated, after 6 years of follow up, a lower incidence of obesity in those 
who consumed olive oil than in those who consumed sunflower oil.319 Another 
randomized trial with ad libitum MD enriched with olive oil or mixed nuts, the 
PREDIMED study, showed no 3-month weight gain with these high-fat diets.308 
Restricted energy diets that were relatively high in fat because they incorporated 
olive oil were effective alternatives to the traditional low-fat diet for initial weight 
loss and maintenance in feeding studies in obese persons.320, 321 A satiating effect 
of olive oil intake with ensuing food compensation might explain its lack of a 
fattening effect. In this regard, experimental evidence has been provided that 
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mobilization of intestinally-derived oleoylethanolamide, a lipid messenger of 
satiety, is enabled by uptake of dietary oleic acid.322 These positive effects 
accounted for by the MD have also been observed in other European region. In a 
recent study including a sample size of almost 500,000 individuals from 10 
Mediterranean, Central, and Northern European countries, the adherence to a 
MD, modified to apply across Europe, was associated with lower waist 
circumference in men and women after controlling for BMI, total energy intake, 
and other potential confounders. Interestingly, the inverse association between 
MD Score and waist circumference was stronger in men and women from 
Northern European regions who were overweight or obese.323 In another 
prospective cohort study (EPIC-PANACEA) in 373,803 individuals from 10 European 
Countries,324 individuals with a high adherence to the MD showed a 5-y weight 
change of -0.16 kg (95% CI: -0.24, -0.07 kg) and were 10% (95% CI: 4%, 18%) less 
likely to develop obesity than individuals with a low adherence to the MD pattern.  
Sex 
Sex differences in the impact of the MD on glucose/insulin homeostasis have been 
documented (see above). Whether these sex-related effects were associated with 
changes in NEFA has been verified in 38 men and 32 premenopausal women (24–
53 y).325 Variables were measured during a 180 min Oral Glucose Tolerance Test 
(OGTT) before and after the MD. A sex-by-time interaction for plasma insulin iAUC 
was found (men: −17.8%, 𝑃 = 0.02; women: +9.4%, 𝑃 = 0.63; 𝑃 for sex-by-time 
interaction = 0.005). A sex-by-time interaction was also observed for insulin 
sensitivity (Cederholm index, 𝑃 = 0.03), for which only men experienced 
improvements (men: +8.1%, 𝑃 = 0.047; women: −5.9%, 𝑃 = 0.94). In contrast, no 
sex difference was observed for glucose and C-peptide responses. Trends toward a 
decrease in NEFA AUC (𝑃 = 0.06) and an increase in NEFA suppression rate (𝑃 = 
0.06) did not show any sex difference. Changes in NEFA were not associated with 
change in insulin sensitivity. Compared to women, more favorable changes in 
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glucose/insulin homeostasis were observed in men. These differences in response 
to the MD are not explained by sex differences in NEFA response. 
Long-term adherence to the MD following a nutritional intervention promoting 
the Mediterranean food pattern in Canadian men and women presenting CV risk 
factors has also been evaluated. 326 The 12-week nutritional program used a 
motivational interviewing approach and included individual and group sessions. A 
food frequency questionnaire was administered to evaluate dietary intakes from 
which a Mediterranean score (Medscore) was derived and the Three-Factor Eating 
Questionnaire allowed for assessing eating behaviors. Measurements were 
performed at baseline and after the 12-week nutritional intervention, and then at 
3 and 6-month post intervention. No gender difference was observed in changes 
in the Medscore during the nutritional intervention and follow-up. However, the 
Medscore returned towards baseline values during follow-up in men and women 
(P <0.0001). Men reported larger decreases in red and processed meat and larger 
increases in whole fruit intakes than women (P = 0.03 and P = 0.04, respectively). 
Men showed a greater decrease in habitual susceptibility to disinhibition than 
women (P = 0.03). A gender by time interaction was found for waist 
circumference, i.e. men having lower waist circumference at the end of the 
intervention as well as at follow-up than at baseline. Women’s waist 
circumference decreased in response to the intervention only (P = 0.05). Changes 
observed in total-cholesterol (C) to HDL-C ratio, triglyceride levels and triglycerides 
to HDL-C ratio were more pronounced in men than in women after the 
intervention as well as at follow-up (P ≤0.03).  
Aging  
Dietary manipulation might be a major tool for partially modifying the structure 
and consequently the features of biological membranes.327 The possibility of 
supporting cell membranes with specific membrane components that are 
characterized by an elevated turnover allows to ameliorate and/or counteract 
modifications induced by the activity of free radicals. If the new fatty acids to be 
54 
 
used in this process are provided in the form of virgin olive oil, a variety of benefits 
are likely to occur. With its very high content of MUFA (mainly oleic acid), olive oil 
greatly enriches all biological membranes so that it partially and gradually replaces 
the other fatty acids, mainly PUFA. This process produces membranes that are less 
susceptible to oxidative injury because of the increased concentration of oleic 
acid. It is important to emphasize that the propagation of lipid peroxidation 
phenomena requires the fatty acids to possess two or more double bonds.327 On 
the other hand, virgin olive oil also contains large amounts of free-radical 
scavengers (e.g. α-tocopherol, several different phenolic compounds and even 
coenzyme Q) that neutralize the toxic species and sometimes even prevent the 
early steps of their formation.328-330 The efficacy of dietary interventions based on 
virgin olive oil to modify the fatty acid pattern of biological membranes making 
them less prone to oxidative modifications, has been widely demonstrated.61, 331-
333 In addition, MUFA lead to favorable changes in the lipid profile of lipoproteins, 
generating LDL particles more resistant to oxidative modifications.334 Therefore, it 
has been suggested that MD might be a new, promising direction in the treatment 
(and in the prevention) of age-related diseases, as a useful adjuvant to the 
corresponding pharmacological therapy.327  
 
MD and Emerging Vascular Risk Factors 
Fatty acids profile 
The beneficial effect of MD is thought to be related to its ability to affect several 
key risk factors.335 Through the intake of antioxidants, fiber, and polyunsaturated 
fats, MD lowers blood pressure and plasma homocysteine concentrations, 
improves endothelial function, and insulin resistance, and decreases the risk of 
thrombosis and of ventricular arrhythmias.32, 259, 336-340 On the other hand, vis-à-vis 
the seminal concept in the Seven Countries Study that 10-yr coronary mortality 
rate was significantly related to sample average saturated fatty acid intake in the 
habitual diet, several authors have emphasized reductions in CV risk -in primary 
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and secondary prevention studies-, when replacing saturated fatty acid intake 
with MUFA and/or PUFA 341-343. FA influence plasma levels of atherogenic 
lipoproteins344 and affect several aspects of inflammation,345 a key mechanism in 
atherothrombosis.346  
Presently, among a variety of debated dietary recommendations to decrease the 
risk of CV disease, reducing the intake of saturated fatty acid (SFA) (or replacing it 
with monounsaturated or polyunsaturated fatty acids) is a priority in CV 
prevention guidelines.347, 348 However, the results of two meta-analyses have 
questioned the link between saturated fat intake and risk.349, 350 Even though the 
FA profile of individuals is influenced by dietary intake - as is the case of LA and 
ALA- it is also endogenously modulated by the activity of specific enzymes.351  
Studies 36, 352-354 indicate that, compared with healthy subjects, patients with CAD 
exhibit higher blood levels of trans fatty acids and SFA and lower levels of PUFA, 
with controversial data about n-6 PUFA, especially AA.355 Blood levels of palmitic 
acid are strongly associated with CAD. 356 Whether, however, blood FA: 1) is an 
index of the quality of food intake; 2) it might be used as a tool to estimate diet 
quality and compliance with a nutritional advice, and 3) the adverse plasma fatty 
acid profile in patients with CAD can be favorably modified by consuming a MD, 
has not been established in previous reports.  
Inflammation 
So far, the beneficial effect of MD against CAD has been accounted for by the 
ability of this dietary pattern to modify traditional risk factors of atherosclerosis. 
Recently, some authors have suggested that the anti-inflammatory effect–at the 
level of the vessel wall- may be key to explain the link between MD adherence and 
low CV mortality.357 There is compelling evidence that inflammation is crucial at all 
stages of the atherosclerotic process.358 Early phases of atherosclerosis (fatty 
streak formation) involve the recruitment of inflammatory cells from the 
circulation, their adhesion to endothelium and migration to sub-endothelial space, 
a complex process which involves adhesion molecules (e.g. interleukin [(IL]) 
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production and up-regulation on endothelial cells and leucocytes.359 Adhesion 
molecule expression on circulating peripheral blood mononuclear cells is a crucial 
step for the firm adhesion of such cells to the endothelium during the 
inflammatory reaction linked to atherosclerosis development.358, 359. Thereafter, 
resident macrophages and lymphocytes become activated and secrete cytokines 
that in turn activate other cell types leading to a self-perpetuating inflammatory 
process in the vascular wall that is instrumental in plaque formation, vulnerability 
and rupture leading to thrombosis.358, 359 Thus, ongoing inflammation is also 
crucial in the development of instability and rupture of atheromatous plaques and 
the development of ischaemic events in most advanced stages of the disease.358, 
359  
Adipose tissue is both a dynamic endocrine organ, and a highly active metabolic 
tissue. Fat produces and secretes adipokines, which play an important role in the 
induction of insulin resistance and in the atherosclerotic process. Visceral 
adiposity is more strongly associated with insulin resistance than subcutaneous 
fat. However, the precise chain of events linking over-nutrition, obesity, activation 
of the innate immune system and reduced insulin sensitivity in peripheral tissues 
remains incompletely understood.360 In a randomized controlled study in 120 
obese women, a multidisciplinary program aimed at reducing weight through 
lifestyle changes (diet and exercise) was associated with reduced levels of CRP and 
IL-6, and increased levels of adiponectin, associated with improved insulin 
sensitivity.361 Mechanisms underlying a dietary intervention in patients at 
increased cardiac risk were also explored357 in 180 patients (99 men and 81 
women) with the MetS randomized to receive a MD-style diet (instructions about 
increasing daily consumption of whole grains, vegetables, fruits, nuts and olive oil) 
vs. a cardiac-prudent diet (less than 30% fat intake). After 2 years, while 
endothelial function improved, body weight decreased more in the intervention 
group than in the control group, but even after controlling for weight loss, 
inflammatory markers, such as IL-6, IL-7, IL-18 and CRP, and insulin resistance 
declined more in the MD intervention group than in the control group. Only 40 
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patients in the intervention group still had MetS after 2 years when compared 
with 78 patients on the control diet.  
Oxidative stress. 
It is long been known that ROS produced by activated leukocytes and 
macrophages are crucial to control invading microorganisms. Now it is clear that 
these intermediary metabolites produced under physiological conditions during 
oxygen metabolism, also play a critical role as signal molecules in health and 
disease. Mitochondria are the most important source of intracellular ROS. 
However, ROS can be generated by a variety of enzymes including oxidases, 
cyclooxygenases and lipoxygenases. The primary ROS produced in the body is 
superoxide anion (O2–), which is generated from a 1-electron reduction of 
molecular oxygen. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
is the main source of O2 – in mammalian cells.362 NADPH oxidase is a 
multicomponent enzyme that has a membrane portion known as cytochrome b558 
(that comprises a large gp91phox, and a smaller p22phox subunit), which is 
inactive until it is associated with the cytosolic component (p47phox, p67phox and 
p40phox). Under physiological conditions, reactive and incompletely reduced 
forms of oxygen are detoxified into water by anti-oxidant defence and repair 
enzymes to maintain a low steady state of toxic oxidants. 363 Steady-state levels of 
O2 – depend on both their rate of production and the activity of a wide array of 
dietary antioxidants and endogenous antioxidant enzymes such as glutathione 
(GSH, reduced form), catalase, and superoxide dismutase (SOD). 364 In plasma, 
glutathione (GSH, reduced form) and glutathione disulphide (GSSG, oxidized form) 
are transported from tissues by concentration-dependent transport systems.365 
Results from animal experiments have shown that the of GSH to GSSG ratio 
(GSH/GSSG) in plasma decreases in response to tissue oxidative stress.366 
Therefore, GSH/GSSG may be preferable to either GSH or GSSG alone as an overall 
indicator of the redox status and to be used as a marker of oxidative stress.367 In 
mammals, there are 3 isoforms of SOD: a cytosolic or copper/zinc (Cu/Zn- SOD), a 
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manganese (MnSOD) localized in mitochondria, and an extracellular form of 
Cu/ZnSOD. Although produced by distinct genes, these 3 SODs catalyze the same 
reaction: dismutation of O2 – into hydrogen peroxide plus molecular oxygen.368 
While an imbalance in the mitochondrial respiratory chain is the main source for 
the generation of abnormally high levels of ROS, an impaired antioxidant capacity 
leads to an excess in the production of ROS as well, and in turn to oxidative stress, 
i.e. to the disruption of the redox signalling and control 369 with subsequent 
oxidation of macromolecules, and tissue damage and dysfunction.370 In particular, 
oxidative stress is involved in major events related to CV disease such as DNA 
damage, tissue remodelling, and alterations in gene expression.371  
Biochemically, GSH/GSSG redox decreases lipid hydroperoxides by reducing these 
peroxides into alcohols and suppressing their generation.372, 373 Decreased lipid 
hydroperoxides, in turn, lower oxidized LDL and slow the atherosclerotic 
process.372, 373 Additionally, a lower GSH/GSSG may result in protein 
glutathionylation and oxidatively altered GSH-GSSG redox signalling367 and 
associated gene expression and apoptosis, which may contribute to 
atherosclerosis. Clinically, an unfavourable GSH/GSSG has been found in patients 
with AMI 374 and has been related to the progression of atherosclerotic lesions 
after percutaneous coronary interventions.375  
Among multiple key factors in the physiology of the endothelium, oxidative stress 
has been identified as a major regulatory mechanism. Current evidence is that MD 
leads to improved redox balance, increased nitric oxide bioavailability and 
decreased availability of pro-inflammatory and pro-oxidant molecules.339, 357, 376, 377 
Old studies from this Institution have reported that phenols -natural antioxidants 
present in virgin olive oil-, affect endothelial function in a dose-dependent 
manner.378 The possibility that key components of MD act synergistically on 
endothelial function through their antioxidant properties has been also addressed. 
The combination of high-phenol virgin olive oil and red wine (rich in antioxidants) 
induce favorable effects on postprandial flow-mediated dilatation in healthy 
young men.379 Although the exact molecular routes underlying these effects are 
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still matter of investigation, hydroxytyrosol (a key phenol antioxidant of virgin 
olive oil) and resveratrol –a major antioxidant of red wine-, both exert their vaso-
protective effects in response to oxidative injury by the activation of the Nrf2 
pathway, which, in turn, promotes the expression of antioxidants, e.g. 
NAD(P)H:quinone oxidoreductase 1.123, 380 Moreover, polyphenols cause nitric 
oxide, and endothelium-derived hyperpolarizing factor mediated relaxation.381  
Compelling evidence suggests an association between oxidative stress and 
obesity/insulin resistance. In nearly 3,000 patients from the Framingham Heart 
Study, an association between increasing body mass index and increasing systemic 
oxidant stress has been reported.382 Data from 2,002 nondiabetic subjects of the 
community-based Framingham Offspring Study indicate that, even after correcting 
for BMI, systemic oxidative stress is associated with insulin resistance in 
individuals at average or high risk of diabetes. (metabolic syndrome or IFG)383 
Short-term (up to six months) caloric restriction in overweight men and women 
produced significant body weight reduction associated with decreased DNA 
damage, another surrogate marker of oxidative stress.384 Finally, individuals at 
high CV risk who improved their diet toward a MD pattern show significant 
reductions in cellular lipid levels and LDL oxidation.385 Adiponectin -a protective 
factor against atherosclerosis and insulin resistance-, plays an important role in 
modulating both insulin sensitivity and concentrations of circulating plasma 
glucose and NEFA, a lower concentration of circulating plasma of NEFA being a 
good predictor of reduced insulin sensitivity and increased risk of T2DM. 386 
Accordingly, a MD-type of diet reduces the need for glucose-lowering drugs and 
improves short-term glucose control more than a low-fat diet in overweight 
patients with newly diagnosed T2DM. 103. Regardless of caloric restriction, a 
prolonged adherence to MD in overweight men results in a rise in circulating level 
of adiponectin, and lowers several markers of oxidative stress.387 In 987 diabetic 
women from the Nurses’ Health Study with no history of CV, the closer the 
adherence to a MD the higher the adiponectin concentration. 388 Of the 
components of the MD pattern, alcohol, nuts, and whole grains show the 
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strongest association with adiponectin concentrations. In insulin-resistant 
offspring of obese T2DM patients, a MD rich in MUFA (23%) improves insulin 
sensitivity, and this is associated with increased postprandial adiponectin mRNA 
gene expression in peripheral adipose tissue.389 All in all, in addition to lowering 
blood pressure, and total cholesterol and triglycerides; increasing HDL-cholesterol, 
and improving insulin sensitivity, a prolonged adherence to MD, with or without 
caloric restriction in overweight or obese men, is associated with reduced 
oxidative stress. The latter changes are amplified when MD is associated with 
calorie restriction and increased physical activity.390 This information is particularly 
important for individuals who carry additional risk factors, such as T2DM, obesity, 
and the metabolic syndrome, and fail, as most do, to have a consistent and long-
term weight loss. 
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Rationale  
Since the first data from the Seven Countries Study,391 several studies carried out 
in different populations have established a beneficial role for the main 
components of MD as to the occurrence of all-cause cardiovascular (CV) disease, 
including CVD and chronic degenerative diseases, malignancy, lipid metabolism, 
blood pressure, and pathophysiological settings such as endothelial dysfunction 
and overweight.392 
A systematic review of prospective cohort studies that have analysed the relation 
between the adherence to several MD scores and the risk of CV mortality in 
primary prevention settings (404,491 subjects), confirmed these findings showing 
that a two point increase in the adherence to MD scores was significantly 
associated with 9% reduction of the risk of cardiovascular mortality, largely 
independent of vascular risk factors (VRFs).393 To this end, a literature-based MD 
score based on nine items that may predict the CV risk at individual level has been 
proposed.394  
Concerning the relationships between MD score and subclinical atherosclerosis 
(as indexed by carotid intima media thickness; c-IMT) and/or its change over time 
(cIMT progression), the results reported in the literature are sparse and often 
inconsistent.34, 242-245, 250 Epidemiological studies investigating the association 
between MLDP and c-IMT progression in large cohorts are completely lacking. 
As to oxidative stress status evaluation, it is increasingly clear that in different 
stages during the atherothrombotic process, abnormally high levels of reactive 
oxygen species (ROS) are generated that can overwhelm antioxidant systems and 
adversely affect cell function by causing oxidative post-translational injury.395 A 
similar altered equilibrium can be found when evaluating both inflammation 
markers and blood fatty acids profile in patients with CVD.396, 397 Indeed, blood 
fatty acids (FA) composition has been implicated in cardiovascular risk, 
presumably through changes in oxidative stress and inflammation, two 
mechanisms involved in the pathogenesis of atherothrombosis.36 Previous data 
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from our group suggest that patients with CAD adhere less to features of MD and 
exhibit a different fatty acid profile compared to healthy subjects.396 
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Aims of the present study 
Primary objectives of the present study were to evaluate:  
1) The relationship between MD adherence and c-IMT progression;  
2) Whether such relationship is similar in populations from different European 
countries with different nutritional patterns/habits (e.g. in people living far from 
the Mediterranean area);  
3) Whether the relationship between MD (or of its components) and baseline c-
IMT burden is consistent with a dose–response relationship or a threshold effect; 
4) Whether the relationship between MD, baseline c-IMT, and clinical events 
involves changes in major and emerging (e.g. inflammation, oxidative stress, and 
FA composition) vascular risk factors.  
5) Whether and to what extent MD adherence relates to inflammatory markers, 
markers of an oxidative stress status, and to FAs profile in males and females with 
a recent history of coronary revascularization. 
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Methods  
For the objectives of the present report, data from two major studies carried out 
in this Institution have been analyzed: the IMPROVE Study and the RISMED Study. 
Additional information concerning these two studies are reported below. 
 
The IMPROVE Study 
Study objectives The primary objective of the IMPROVE study was to evaluate the 
association between Mediterraneran-like dietary pattern (MLDP) and c-IMT 
progression over 15 months and to assess whether c-IMT progression was an 
independent predictor of risk of future vascular events (VEs) (AMI, cardiovascular 
death, stroke, or any intervention in the carotid, coronary, or peripheral arterial 
districts) occurring from the 15th to the 36th month in the follow-up. To achieve 
this goal the 3-year follow-up was split into two time periods: from 0 to 15 months 
to measure the c-IMT changes over time and from 15 to 36 months to collect 
VEs.249  
Study design.  
The design and the major results of the IMPROVE studies have been published 
elsewhere.249, 398 Briefly, the IMPROVE study is a multicenter, longitudinal, 
observational study, funded by European Union (EU) within the Vth framework 
program, which involves seven recruiting Centers in five European countries: 
Finland (two Centers), France, Italy (two Centers), the Netherlands, and Sweden. 
The study was designed according to the rules of Good Clinical Practice (GCP), and 
the ethical principles established in the Declaration of Helsinki. Each participant 
provided two different informed consents; one for general participation in the 
study and one for genotyping.247 The protocol was designed for a study duration 
of 36 months. Recruitment of a total of 3,598 patients (514 per center) was 
targeted. About 21,000 subjects were screened: 3,400 in Milan, 1,450 in the first 
Kuopio center and 2,354 in the second, 4,239 in Stockholm, 4,050 in the 
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Netherlands, 3,804 in Perugia, and 1,800 in Paris. Men and women, aged from 55 
to 79 years, with at least three VRFs, asymptomatic for cardiovascular diseases 
and free from any conditions that might limit longevity or c-IMT visualization were 
considered as eligible for the study. Individuals who met the eligibility criteria and 
who signed both informed consents were enrolled in the study. Due to its 
observational nature, participation did not require any change in medication(s).247 
A total of 3,711 individuals were enrolled, aged 54-79 years were enrolled. All 
participants never had a cardio- or cerebro-vascular event before enrolment and 
all have at least three VRFs. Subjects were considered to be exposed to a VRF 
when one of the following criteria was satisfied: male sex or at least 5 years after 
menopause for women; hypercholesterolemia (mean calculated LDL-C blood levels 
> 160 mg/DL or treatment with lipid lowering drugs); hypertriglyceridemia 
(triglycerides levels > 200 mg/DL after diet or treatment with triglycerides 
lowering drugs); hypoalphalipoproteinemia (HDL-C < 40 mg/DL); hypertension 
(diastolic blood pressure > 90 mmHg and/or systolic blood pressure >140 mmHg 
or treatment with anti-hypertensive drugs); diabetes or impaired fasting plasma 
glucose (blood glucose level > 110 mg/DL or treatment with insulin or oral 
hypoglycemic drugs);399 smoking habits (at least 10 cigarettes/day for at least 
thirty months); family history of cardiovascular diseases. Exclusion criteria were: 
age under 54 or over 79 years; abnormal anatomical configuration of neck and 
muscles, marked tortuosity and/or depth of the carotid vessels and/or uncommon 
location of arterial branches; personal history of AMI, angina pectoris, stroke, TIA, 
aortic aneurysm, intermittent claudication, surgical intervention of 
revascularization in carotid, coronary or peripheral arterial territories, CHF (III-IV 
NYHA Class); and history of serious medical conditions that might limit longevity 
(e.g. cancer).249 
Ultra sonographic protocol.  
Carotid ultrasound was performed using seven identical ultrasonic machines 
(Technos system, ESAOTE), equipped with 5-10 MHz linear array probes. All 
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machines were identically calibrated. Calibration was checked with a phantom 
before the start of the study and after 1 year. Sonographers and readers were 
trained and certified by the coordinating Center (Department of Pharmacological 
and Biomolecular Sciences) in Milan. The far walls of the left and right common 
carotid (CC), the bifurcation (BIF) and the internal carotid artery (ICA) were 
visualized in anterior, lateral and posterior angles and recorded on sVHS 
videotapes. Images were acquired with the subject’s head rotated approximately 
45° opposite to the side being imaged and the three angles were acquired with the 
transducer held approximately at 45°, 20° and 60° from the vertical. Each selected 
image of the CCs (in their entire length), the BIFs, and the first proximal 
centimeter of the ICAs were measured in at least three different frames randomly 
distributed within the cardiac cycle. In order to explore the influence of the 
cardiac cycle on IMT measurements, in a subsample of 100 subjects, CC-IMTmean 
was re-measured using a dedicated software, 400 which allows continuous 
measurements of IMT within 3 to 5 beats, thus allowing recording of the kinetics 
of IMT changes associated to cardiac cycle. Peak systolic and end-diastolic IMT 
measurements, as well as their average, were then compared with IMT 
measurements obtained according to the IMPROVE protocol without 
electrocardiographic synchronization. Preliminary data showed that IMT 
measurements obtained with the IMPROVE protocol (0.667±0.172 mm) well fitted 
with the mean value (0.665±0.172) of IMT measurements obtained in peak systolic 
(0.631±0.164 mm) and end-diastolic (0.699±0.172 mm) phases, with a very good 
correlation (r = 0.9993) and a minimal bias. In each carotid segment (1 cm length), 
both mean and maximal IMT were evaluated. Plaques were incorporated into 
these measurements. Eleven C-IMT variables were considered: 1stCC-IMTmean, 
1stCC-IMTmax, CC-IMTmean, CC-IMTmax, BIF-IMTmean, BIF-IMTmax, ICA-IMTmean, ICA-
IMTmax, IMTmean, IMTmax and IMTmean-max. 1stCC-IMTmean is the average of six mean 
IMT values obtained by measuring both left and right CC (1 cm length proximal to 
the bifurcation) in the 3 angles (anterior, lateral and posterior). The greatest 
among all the maximal IMT values measured in each one of these six 1stCC 
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segments (two carotids x three angles) was defined 1stCC-IMTmax. CC-IMTmean is the 
average of all mean IMT values obtained from left and right CC visualized in their 
entire length (excluding the 1st cm) with sequential probe movements of 1 cm 
length, according to the 3 scan angles (anterior, lateral and posterior). The total 
number of segments visualized ranged from 6 to 24 according to the subject’s 
length of the neck. In each segment, the software automatically provided also the 
maximal IMT value. The greatest among all the maximal IMT values detected in 
each one of the 6 to 24 CC segments was defined as CC-IMTmax. BIF-IMTmean is the 
average of six mean IMT values obtained by measuring both left and right BIF (1 
cm length) in the 3 angles (anterior, lateral and posterior). The greatest among all 
the maximal IMT values measured in each one of these 6 BIF segments (left and 
right Bif x three angles) was defined BIF-IMTmax. ICA-IMTmean is the average of six 
mean IMT values obtained by measuring both left and right ICAs (the 1st cm 
proximal to bifurcations) in the 3 angles (anterior, lateral and posterior). The 
greatest among all the maximal IMT values measured in each one of these 6 ICA 
segments (left and right ICA x three angles) was defined ICA-IMTmax. Composite 
variables (IMTmean, IMTmax and IMTmean-max) refer to the whole carotid tree:  
IMTmean is the average of 1stCC-IMTmean, CC-IMTmean, BIF-IMTmean and ICA-IMTmean. 
IMTmax is the greatest value among 1stCC-IMTmax, CC-IMTmax, BIF-IMTmax and ICA-
IMTmax.  
IMTmean-max is the average of 1stCC-IMTmax, CC-IMTmax, BIF-IMTmax and ICA-IMTmax.  
About 62% of participants were followed throughout the study by the same 
sonographer, and all scans for each subject were assigned to a single reader after 
coding and were read blindly in the centralized laboratory of Milan using a 
dedicated software (M’Ath, Metris SRL France).401 These measurements were not 
reported to patients. The total number of carotid plaques (IMTmax >1.5 mm) in 
each carotid segment and in the whole carotid tree (also normalized according to 
the number of segments actually visualized) and the number of non-visualized 
carotid segments were also recorded. To evaluate changes of C-IMT over time, 
ultrasonographic measurements were repeated at 15 months using the same 
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ultrasonographic protocol (positions and angles of ultrasound transducer with 
respect to the neck) used at baseline. C-IMT change for each ultrasonographic 
variable, expressed in mm/year, was calculated as the difference between the 15-
month measurement and the corresponding baseline value divided by the length 
of the time of intervention.  
The variables selected for the statistical analyses were the changes per year of 
mean and maximum IMT values of the first centimeter of CC proximal to the 
bifurcation (1stCC-IMTmean-progr and 1stCC-IMTmax-progr), of the remaining part of CC 
(CC-IMTmean-progr and CC-IMTmax-progr), of BIF (Bif-IMTmean-progr and Bif-IMTmax-progr) 
and of ICA (ICA-IMTmean-progr and ICA-IMTmax-progr) as well as the changes of the 
mean, maximum and mean-maximum IMT values of the whole carotid tree 
(IMTmean-progr, IMTmax-progr, and IMTmean-max-progr). To explore hypothesis that vascular 
risk may be better associated with a focal rather than diffuse progression and that 
the maximal change may occur in any site regardless of its location and its initial 
size, the “Fastest-IMTmax-progr”, i.e. the greatest value chosen among the 
progressions of IMTmax detected in the eight carotid segments measured was also 
considered. Examples of the Fastest-IMTmax-progr in three subjects are shown in 
(Supplemental Figure IV). The precision of the ultrasonographic measurements at 
baseline has been reported.247, 398  
Laboratory analyses.  
Laboratory analyses were performed at baseline and at month 30. Several 
biological samples were kept in a biobank. Specifically, the biobank contains 14 
aliquots of 0.5 mL EDTA plasma and 8 aliquots of 0.5 mL serum for each subject. In 
addition, for each subject, 2 x 5 mL whole blood was stored for DNA extraction. 
DNA was purified (in the Atherosclerosis Research Unit, Karolinska Institute 
Stockholm, Sweden) from all patients who signed informed consent for genetic 
studies. Blood sampling for laboratory tests was performed after an overnight fast. 
Plasma glucose concentration, blood cell count, hematocrit and differential counts 
were measured locally. Blood for centralized biochemical analyses was kept at 
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room temperature for a minimum of 30 min to allow clotting to occur. Serum, 
prepared by centrifugation at 2,000g for 20 min, was dispensed in polypropylene 
tube and frozen at –80oC prior to shipment for centralized biochemical analyses 
and biobanking in Stockholm (Karolinska Institute Stockholm, Sweden). Serum 
concentrations of total, HDL and LDL cholesterol (by Friedewald's formula), 
triglycerides, uric acid, high-sensitive C-reactive protein (hs-CRP) and creatinine 
were analyzed in a centralized laboratory in Stockholm (Department of Clinical 
Chemistry, Karolinska University Hospital Solna, Stockholm, Sweden) with the use 
of LX Beckman instruments. Cholesterol, triglycerides and uric acid were measured 
with enzymatic methods, creatinine with colorimetry-alkaline picric and hs-CRP 
with turbidimetry (NIPIA methods). Additional information concerning methods 
for laboratory analyses have been reported.247  
Nutrition variables, physical activity, smoking habits, and psychosocial variables. 
Milk, wine, beer, spirits consumption and total amount of alcohol were recorded 
in terms of “DL/day”. Fruit consumption was recorded in terms of “pieces a day”. 
The consumption of meat, fish and eggs was recorded in terms of “times a week”. 
The consumption of tea and coffee was recorded in terms of “times a day”. 
Although collected in a semi-quantitative way, these variables were used in the 
analyses in terms of consumers (>0) or not consumers (=0). The main type of fat 
consumed (lard, butter, olive oil, seed oil, margarine) and the type of milk 
consumed (not skimmed, semi-skimmed, skimmed) were also recorded.247 
Quality control.  
Standard operating procedures (SOPs) Before the start of the study, investigators 
were provided with detailed Standard Operating Procedures (SOPs) and were 
required to abide by them, in conformity with GCP. Case Report forms (CRFs) Data 
were collected using electronic CRFs allowing automatic control of all entered data 
by logic controls and range checks, and easy identification of missing data. Once 
compiled, each file was sent to the data management Center (DMC) and included 
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into the central database without any further typing. Confidentiality of data 
Information about participant identity (name, address, phone number and identity 
in the study) was retained at each recruitment center. To protect confidentiality, 
all information transferred to the central DMC (University of Milan) was 
anonymized. Monitoring of data quality was performed by regular site visits, mail 
and telephone interviews. Record retention. Each principal investigator retains 
copies of all relevant information for a period of 15 years after the completion of 
the study.247  
 
The Mediterranean-Like Dietary Pattern (MLDP) score.  
At baseline, dietary intake maintained during the year preceding enrolment was 
assessed by a semi-quantitative 11 items food-frequency questionnaire, 
administered by trained personnel. A MLDP score adherence score analogous to 
the Greek Mediterranean Index 24 and based on only seven nutritional items 
(fruits, fish, wine, olive oil, meat, milk and eggs) was then constructed. Since the 
amount and type of vegetables, legumes, nuts and cereals consumed largely 
differs among populations 402, the items included in the questionnaire were 
limited to foods well diffused in all the countries involved. For fruit or fish, high 
consumption (top tertile of their distributions, i.e. fruit ≥3 servings/day and fish >2 
times/week) was scored one, other intakes received 0 points; for meat, eggs or 
milk a low intake (bottom tertile of their respective distributions, i.e. meat <2 
times/week, eggs ≤1 times/week, milk ≤3 DL/day) received 1 point. A predominant 
consumption of olive oil, rather than of other types of fat, and a moderate 
consumption of wine (1-2 glasses/day) also received one point. Based on the scale 
obtained, score 0 indicates minimal adherence and score 7, maximal adherence to 
MLDP. Such MLDP was adopted being its indices inversely associated with the 
incidence of stroke in a recent Italian study. 403 The predictive performance of the 
MLDP score was first validated versus the incidence of vascular events and then 
tested versus primary endpoints (i.e. 15-mo c-IMT progression). Because a 
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standardized questionnaire and a common clinical and subclinical assessment 
were used, the results for the entire cohort could be readily compared among 
IMPROVE centers and among EU. Besides diet, IMPROVE also included a baseline 
assessment of socio-demographic, anthropometric, lifestyle, clinical and 
biochemical measures.  
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The RISMED Study 
Study objectives  
The RISMED Study was a randomized, parallel groups, open-label, intervention 
trial in which a 3-mo intensively advised MD was tested vs. an usual low-fat 
dietary advice to assess: 1) the possibility to favorably modify the adverse plasma 
fatty acid (FA) profile in patients with CAD by consuming a MD; 2) the effect of a 
MD on the oxidative balance and on indices of systemic inflammatory activity, and 
the relationship between these potential changes and the modification of the 
blood FA pattern, and 3) whether blood FA is an index of the quality of food intake 
and whether it might be used as a tool to estimate diet quality and compliance 
with a nutritional advice.  
Study design  
Participants (n= 75 per arm) were males and females, age 30-75, with a recent 
history of coronary revascularization, randomized after clinical stabilization (at 
least 60 days after any coronary procedure or event). Blood parameters (blood FA, 
total cholesterol, LDL-C, HDL-C, triglycerides, glucose), anthropometric variables 
(weight, height, waist circumference and BMI), blood pressure and heart rate 
were measured at randomization ad at the end of the treatment. Exclusion criteria 
were: patients with diabetes mellitus, food intolerance, BMI < 19 or > 33, or those 
who assume drugs or food supplements with omega-3 FAs or natural or synthetic 
antioxidants.  
Nutritional advice.  
MD was personalized in term of total calories, and included: fatty fish at least 3 
times a week; legumes 2-3 times a week; raw or cooked vegetables (preferably 
antioxidant-rich), twice a day; fresh fruits twice a day; 30 to 45 g olive oil a day; 
men: 1-2 glasses of red wine a day, women: 1 glass of red wine a day; not more 
than 150 g red meat a week. Cold cuts, sweets, cakes, butter, fatty cheese were 
73 
 
discouraged. The control group received dietary counselling for mild weight loss 
(when needed) and low intake of saturated fats (<10% of total energy) and sugar 
rich foods. Dietary assessment was administered at enrolment by a validated 
dietary recall tool, the EPIC FFQ (food frequency questionnaire). Compliance to the 
assigned diet was assessed at the middle of the study using a 7-day food diary. The 
score proposed by Trichopoulou et al24 was computed in both groups as a 
measure of adherence to the MD. A 7- day dietary recall was administered during 
the second month of the study to assess participants’ compliance. Food and 
macronutrient intake throughout the year before inclusion was also estimated at 
enrolment using a validated FFQ of the EPIC, administered by a registered 
nutritionist. To assess whether blood FA is a reliable index of the quality of food 
intake, data obtained with the FFQ were correlated with the level of classes and 
specific types of FA in blood. Moreover, the change between baseline and final 
levels of FA classes and types were correlated with the compliance to the MD as 
assessed through a 7-day dietary recall performed at the middle of the study, a 
higher compliance with diet being associated with greater changes in levels of FA. 
Laboratory analyses.  
Blood and urinary samples were used for routine biochemical determinations. For 
blood FA analysis, whole blood, obtained from a fingertip of fasting subjects, was 
collected on a special adsorbent embedded with the antioxidant 
butylhydroxytoluene (Blood Collection kit, Sigma-Aldrich, St. Louis, MO). FA 
methyl esters, directly prepared by transesterification, were analyzed by gas liquid 
chromatography at oven temperature from 120 °C to 235 °C.404 The following 
indices of oxidative stress and systemic inflammatory activity were determined at 
randomization and at the end of the study: hs-CRP; whole blood reduced 
glutathione (GSH) and its oxidized form (GSSG). hs-CRP was measured by 
immunoturbidimetry. Newly developed methods were used to measure GSH and 
GSSG. Each will be described in detail below together with the method employed 
for determining blood FA profile. 
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FAs profile determination.  
Advantage of this method mainly consists in the fact that the profile of FAs reflects 
both plasma and red blood cell composition. Blood sampling is performed at the 
beginning and at the end of the study by fingertip puncture with an automatic 
punctured pen for diabetics with a disposable lancet. Blood drops are collected on 
an adsorbent paper strip (Sigma-Aldrich) suitable for chromatographic analysis of 
FA. Such paper contains two areas of 1.4 cm2 each allowing for the collection of 
about 50 µl of blood that can be easily removed for extraction of FAs analysis. To 
avoid the degradation of the FA throughout the storage period, the adsorbent 
paper is soaked with the antioxidant butylhydroxytoluene (BHT) in ethanol (5 
μg/μl) prior to sampling. To prevent degradation of the blood sample, once the 
blood is dried, the chromatographic strips are packed in individual envelopes 
(Ziplock), with the addition of a silica scrubber, and the samples are stored at -19° 
C for ≈two weeks. Preliminary studies documented that: 1) no chromatographic 
peak attributable to the adsorbent paper is detected in the chromatographic 
analysis of FAs, and 2) the samples treated according to this method are stable up 
to a few years. For the determination of the FA, a portion of chromatographic 
paper (1cm2) with the blood sample is transferred into vials with a sealed cap and 
a teflon protective seal. Each vial is added with 0.6 ml of 3N methanol solution in 
hydrochloric acid (Supelco) and the vial is placed in a dry thermostat bath at 90° C 
for 1 hour (Liebish Laboratechnick). After FA methylation and cooling in a cold 
room at 4° C, 1 ml of water; 1 ml of KCl saturated solution, and 400 μl of n-hexane 
are added to each vial to continue FAs methyl esters (FAME) extraction. After 
agitation, samples are centrifuged for 8 minutes at 3,250 rpm at a temperature of 
6° C to facilitate phase separation and extract the supernatant containing the FA 
methyl esters. Finally, FAMEs are analyzed by injecting approximately 0.5 μl of 
each sample into the GC 2010 Shimadzu gas chromatograph equipped with PTV 
injector and FID detector and connected to a dedicated DDS 1000 software for 
data collection and processing. The auxiliary gas employed is helium, and the 
column used is a DB-FFAP (Agilent) with a length of 15 m, an inside diameter of 10 
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mm and a film of 0.10 μm thick. The temperature of the column chamber is 
programmed as follows: an increase of 25°C/minute from 150° C to 205° C, 
isotherm at 205° C for 5 minutes, a further increase of 25° C / minute to 220° C, 
isotherm at 220° C for 2 minutes and finally an increase of 8°C/min to 248° C 
which is maintained for the next 9 minutes. Since a rapid gas chromatograph is 
used, with a run time of 19 minutes and 80 seconds each, the pressure is a higher 
than expected based on information from usual gas chromatographs (≈7.5 bar). 
This increment allows for the detection of FAs with a carbon number ranging from 
14 to 24. When processed with the appropriate software, the chromatograms 
obtained allow the data to be expressed as percentage values of the total FAs. 
Product to precursor ratios of specific FAs are calculated as surrogates of the 
activity of specific enzymes involved in FA metabolism; C16:1n-7/C16:0 ratio 
estimated Δ9 stearoyl-CoA desaturase-1 (SCD1) and C18:3n-6/ C18:2n-6 ratio 
estimated Δ6 desaturase (D6D). 404 The reproducibility of this analytical method 
has been tested by analyzing samples of old methylated FAs from a single subject 
to which, on the same day, two blood samples were analyzed over three different 
time periods (the same day, after one week and three weeks after storage) and 
three blood samples analyzed in the same day but picked up respectively at 
fasting, before the lunch and two hours after the meal. 
Measurement of GSH and GSSG.  
Chemicals and reagents: -l-Glutamyl-l-Cysteinyl-Glycine (GSH), -l-glutamyl-
lcysteinyl-glycine disulfide (GSSG), trichloroacetic acid (TCA), 
ethylenediaminetetraacetic acid (EDTA) and all HPLC grade and LC–MS grade 
solvents were purchased from Sigma–Aldrich (St. Louis, MO, USA). 
Chromatographic columns were purchased from Phenomenex (Torrance, CA, 
USA). Millex®-GV Syringe filter units (13 mm, 0.22 m) were obtained from 
Millipore (Bedford, MA, USA).405 
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Method development and validation  
GSH and GSSG were measured on whole blood added with 10% trichloroacetic 
acid (TCA) in 1 mM EDTA solution to precipitate proteins and stored at -80°C until 
analysis. Levels of GSH and GSSG were assessed by LC-MS/MS method using a TSQ 
Quantum Access (Thermo Fisher Scientific, San Jose, CA, USA) triple quadrupole 
mass spectrometer coupled with ESI operated in MRM in positive mode. 
Separation of analytes was carried out on a Luna PFP analytical column (100x2.0 
mm, 3 µm, Phenomenex, Torrance, CA, USA). The LC mobile phases were: (A) 
ammonium formate 0.75 mM adjusted to pH 3.5 with formic acid and (B) 
methanol. Separation was performed under isocratic conditions with 99% mobile 
phase A at flow rate of 200 µL/min and a column temperature of 35°C. The MRM 
for GSH (m/z 308.1→m/z 76.2 + 84.2 + 161.9) and GSSG (m/z 613.2→m/z 230.5 + 
234.6 + 354.8) were performed with collision energy optimized for each 
compound. Levels of GSH and GSSG were expressed as µmol/g Hb. 
 
Calibration standards and quality controls  
Stock solutions of GSH and GSSG were prepared at 1 mM in 10% TCA solution and 
stored at -80°C. Calibrators containing both GSH and GSSG were prepared daily by 
diluting the stock solutions with 0,1% formic acid. In-house quality control (QC) 
samples of 3 different concentrations levels (GSH: 8, 2, 0.5 µM and GSSG: 1, 0.25, 
0.625 µM), were prepared daily. A pooled whole blood supernatant (PWBS) was 
aliquoted and stored at -80°C and used in the validation procedures. 
 
Linearity, calibration, and matrix effects evaluation.  
Linearity of the assays was assessed by repeated (n=3) analysis of calibrators with 
concentrations ranging from 0 to 100 µM. Calibration curves were prepared in the 
concentration ranges between 0.5-8 µM and 0.0625-1 µM for GSH and GSSG 
respectively. The curves were constructed by plotting the peak area vs the analyte 
concentration. Linear regression analysis was used to determine the slope, 
intercept, and correlation coefficient (r). Calibration curves were prepared both in 
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0.1% formic acid and in 400-fold diluted PWBS to evaluate potential matrix effects 
by comparing the slope of the standard calibration curve with the slope of matrix-
matched standard curve. 
 
Precision, accuracy and recovery. 
Intra-day precision was evaluated by replicate preparations and analysis of quality 
controls (QCs) (n=6) and of PWBS (n=6) performed on the same day. To assess the 
inter-day precision, the same analyses were repeated on 3 different days. Intra-
day and inter-day precision was expressed as coefficient of variation (CV). 
Accuracy was evaluated in “standard addition” experiments. The same GSH and 
GSSG amounts used for QCs were spiked into both PWBS (n=6) and 0.1% formic 
acid, and then quantified. Accuracy was evaluated by comparing the estimated 
(measured) with the added (true) concentrations. Accuracy (bias, %) was 
expressed as: ((Measured value – True value)/ True value) x100. Recovery (%) was 
evaluated by adding the same GSH and GSSG amounts, used for QCs, into fresh 
collected whole blood samples (n=6) kept on ice, before the TCA precipitation. 
 
Lower limit of detection (LOD) and quantification (LLOQ)  
The LOD of an individual analytical procedure is the lowest amount of analyte in a 
sample that can be detected, but not necessarily quantified, as an exact value. It 
was assessed as the smallest detectable signal in diluted whole blood supernatant, 
above baseline noise (signal to noise ratio, S/N =3). The LLOQ (i.e. the lowest 
amount of analyte in a sample that can be quantitatively determined with suitable 
precision and accuracy) was defined as the concentration of GSH and GSSG when 
their signal was 10 times that of the blank (S/N=10). 
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Statistical analyses  
The IMPROVE study  
Quantitative variables were summarized as mean ± standard deviation (SD), or 
median (interquartile range) when appropriate. Variables with skewed 
distributions were log-transformed before analysis. Baseline characteristics of 
subjects, stratified by MLDP score categories, were compared by linear regression 
and chi-square for trend, as appropriate. Multivariable linear regression with 
stepwise selection was employed to identify independent predictors of MLDP. In 
the validation analysis, the association between MLDP score and VEs was assessed 
by three Cox models: Model-1: unadjusted. Model-2: adjusted for age, gender and 
stratified by latitude. Model-3: as model 2 plus lifelong exposure to cigarette 
smoking (pack-years), body mass index (BMI), education (as indexed by years of 
school), physical activity, occupation (categorized as: 1, white collars; 2, service 
workers and 3, manual workers), plasma concentrations of LDL and HDL 
cholesterol, triglycerides, glucose, hs-CRP, creatinine, pulse pressure, antiplatelet 
and statin treatments. Kaplan-Meier curves stratified by classes of MLDP score 
were also computed. The relationship between MLDP score and c-IMT or c-IMT 
progression was evaluated by linear regression models adjusted for the same set 
of covariates as Cox models. In the case of c-IMT progression, the analyses were 
also adjusted for the corresponding c-IMT baseline value. A further Cox model was 
run including model 3 covariates plus baseline c-IMT and Fastest-IMTmax-progr. 
All tests were two-sided and carried out by the SAS statistical package v. 9.4 (SAS 
Institute Inc., Cary, NC, USA). 
The RISMED study 
Continuous variables are presented as mean±SD, and differences between two 
groups (LFD and MD) were compared using the t-test for independent samples. 
Categorical variables were reported as frequency and percentages, and they were 
compared using the chi-square test. The association between MD and Oxidative 
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stress status and between oxidative stress and single items of the Mediterranean 
diet were testing by Pearson correlation. A p value <0.05 was considered 
statistically significant. All data were collected in an Excel database and analyses 
were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina). 
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Results 
The IMPROVE Study 
Baseline characteristics of participants with and without VEs are shown in table 1. 
Mean age was 64.2 years, and 47.9% of subjects were males. A total of 514 
(13.9%) participants were free from relevant pharmacological treatments. 
Starting from the 15-month visit, at which time changes in C-IMT were assessed, 
the median follow-up was 21.5 months (interquartile range, 20.8–22.7). Among 
the 3,482 subjects included in the analysis, 129 (3.7%) developed a VE in the 
follow-up period: 15 had an AMI (0 fatal), 26 were hospitalized for angina pectoris, 
24 underwent angioplasty, and 10 coronary bypass grafting. There were 2 sudden 
cardiac deaths; 21 ischemic strokes (0 fatal); 22 TIAs, 2 peripheral 
revascularization, and 7 new diagnoses of intermittent claudication. Twenty-one 
participants had >1 VE during the follow-up. The baseline characteristics of 
subjects with and without incident VEs are shown in Table 1. Fewer than 10% of 
all subjects changed their medications during follow-up.  
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Table 1. Baseline characteristics of participants without and with VEs 
 
Data are mean±SD and median (interquartile ranges) for continuous variables or number (percent) 
of subjects in group for categorical variables. Duration of smoking, Cigarettes/day, Pack-years have 
been calculated excluding never smokers; P values were calculated by Wilcoxon Rank-Sum Test or 
by Chi-square when appropriate.  
 
Without events 
(n = 3353) 
With events 
(n = 129) P value 
 Kuopio, n (%) 936 (27.9) 42 (32.6)  
 Stockholm, n (%) 497 (14.8) 18 (13.9)  
 Groningen, n (%) 443 (13.2) 31 (24.0)  
 Paris, n (%) 460 (13.7) 10 (7.8)  
 Milan, n (%) 520 (15.5) 14 (10.9)  
 Perugia, n (%) 497 (14.8) 14 (10.9) <0.001 
Anthropometric Variables    
 Men, n (%) 1591 (47.5) 72 (55.8) 0.06 
 Age (years) 64±5 65±6 0.02 
 BMI (Kg/m2) 27.2±4.2 27.7±4.7 0.20 
 Waist/Hip ratio 0.9±0.1 0.9±0.1 0.22 
 DBP (mmHg) 82±10 82±10 0.91 
 SBP(mmHg) 142±18 145±21 0.05 
Smoking habits    
 Current smokers, n (%) 479 (14.3) 29 (22.5)  
 Former smokers, n (%) 1229 (36.7) 53 (41.1)  
 Never smokers, n (%) 1642 (49.0) 47 (36.4) <0.01 
 Pack-years 10.7±16.9 14.4±16.2 0.01 
Biochemical risk factors    
 Total Cholesterol (mmol/L) 5.49±1.13 5.43±1.03 0.53 
 HDL Cholesterol (mmol/L) 1.27±0.36 1.17±0.29 <0.001 
 Triglycerides (mmol/L) 1.29 (0.92,1.87) 1.44 (1.08,2.11) 0.06 
 LDL Cholesterol (mmol/L) 3.55±1.01 3.52±0.94 0.72 
 Uric Acid (µmol/L) 313.8±71.6 324.4±71.4 0.10 
 hs-CRP (mg/L) 1.80 (0.75, 3.50) 2.16 (0.73, 4.42) 0.10 
 Blood Glucose (mmol/L) 5.5 (4.95, 6.3) 5.6 (5.1, 6.5) 0.11 
 Creatinine (µmol/L) 78.9 (68.1, 90.4) 81.4 (72.5, 94.4) 0.47 
 Framingham risk score 22.2 (14.6, 33.8) 29 (17, 44.6) <0.001 
Framingham risk score classes:    
≤5%, n (%) 40 (1.24) 1 (0.83)  
>5, ≤10%, n (%) 339 (10.5) 7 (5.8)  
>10, ≤15%, n (%) 520 (16.1) 18 (14.9)  
>15, ≤20%, n (%) 520 (16.1) 10 (8.3)  
>20%, n (%) 1806 (56.0) 85 (70.3) 0.01 
Pharmacological treatments    
Lipid lowering drugs, n (%) 1384 (41) 45 (35) 0.15 
Statins, n (%) 1349 (40) 43 (33) 0.12 
Fibrates, n (%) 261 (8) 7 (5) 0.32 
Fish oil, n (%) 115 (3) 4 (3) 0.84 
Antihypertensives, n (%) 1889 (56) 74 (57) 0.82 
Beta blockers, n (%) 774 (23) 39 (30) 0.06 
Calcium antagonists, n (%) 535 (16) 22 (17) 0.74 
ACE inhibitors, n (%) 655 (20) 18 (14) 0.12 
Sartans, n (%) 505 (15) 20 (16) 0.89 
Diuretics, n (%) 769 (23) 30 (23) 0.93 
Insulin, n (%) 123 (4) 8 (6) 0.14 
Estrogens supplementation, n (%) 213 (6) 2 (2) 0.03 
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Adherence to MLDP 
Patient’s characteristics according to classes of MLDP score are detailed in Table 2. 
MLDP score was negatively and significantly associated with almost all traditional 
VRFs. As expected the proportion of participants with a MLDP score >3 was the 
highest in Italy, intermediate in France and the lowest in northern Europe (Figure 
3)  
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Table 2. Patient’s characteristics according to classes of MLDP score
 
Values are mean ± SD, or median (interquartile range) or n (%). P values were calculated by linear 
regression or by chi square for trend.  
Characteristics 
MLDP SCORE 
0-1 
(N=1098) 
MLDP SCORE 
2-3 
(N=1868) 
MLDP SCORE 
4-7 
(N=737) 
P-trend 
Latitude     
Kuopio 472 (43) 520 (27.8) 56 (7.6)  
Stockholm 177 (16.1) 291 (15.6) 64 (8.7)  
Groningen 319 (29.1) 191 (10.2) 17 (2.3)  
Paris 68 (6.2) 275 (14.7) 158 (21.4) <0.0001 
Milan 37 (3.4) 282 (15.1) 234 (31.8)  
Perugia 25 (2.3) 309 (16.5) 208 (28.2)  
Vascular Risk Factors     
Framingham Risk Score 
27.4 (18.7, 
40.7) 
22.1 (14.3, 
33.0) 
17.5 (11.2, 
27.6) 
<0.0001 
European Score 5.4 (3.2, 9.0) 3.8 (2.3, 6.7) 2.9 (1.8, 5.1) <0.0001 
Male 580 (52.8) 919 (49.2) 275(37.3) <0.0001 
Age 64.8 ± 5.4 63.9 ± 5.31 63.9 ± 5.7 0.0001 
BMI (kg/m2) 28.4 ± 4.43 27.18 ± 4.22 25.83 ± 3.64 <0.0001 
Waist/hip ratio 0.93 ± 0.09 0.92 ± 0.09 0.9 ± 0.09 <0.0001 
DBP (mm Hg) 84 ± 10 82 ± 10 79 ± 9 <0.0001 
SBP(mm Hg) 147 ± 18 142 ± 18 135 ± 18 <0.0001 
Hypertension 844 (76.9) 1288 (69.0) 420 (57.0) <0.0001 
Diabetes mellitus 375 (34.2) 425 (22.8) 113 (15.3) <0.0001 
Smoking habits     
Never smokers 498 (45.4) 878 (47) 407 (55.2)  
Former smokers 398 (36.2) 727 (38.9) 246 (33.4) <0.0001 
Current smokers 202 (18.4) 263 (14.1) 84 (11.4)  
Pack-years 20 (9, 33.2) 17 (7.8, 28.1) 
16.3 (7.5, 
30.0) 
0.03 
Family history of:     
Coronary artery Disease 738 (70.7) 1170 (64.7) 407 (57.8) <0.0001 
Cerebrovascular Disease 374 (34.1) 689 (36.9) 259 (35.1) 0.49 
Peripheral vascular 
disease 
118 (10.7) 236 (12.6) 89 (12.1) 0.3 
Social Class     
Office work 322 (32.0) 743 (42.9) 314 (47.7)  
Service work 374 (37.2) 562 (32.4) 202 (30.7) <0.0001 
Manual work 309 (30.7) 428 (24.7) 142 (21.6)  
Study years 10.0 ± 3.4 10.6 ± 4.1 10.5 ± 4.2 0.002 
Biochemical variables     
Total Cholesterol, mmol/L 5.32 ± 1.11 5.47 ± 1.12 5.8 ± 1.12 <0.0001 
HDL Cholesterol, mmol/L 1.23 ± 0.36 1.26 ± 0.36 1.32 ± 0.37 <0.0001 
Triglycerides, mmol/L 
1.31 (0.94, 
1.91) 
1.31 (0.94, 
1.91) 
1.28 (0.9, 
1.8) 
0.09 
LDL Cholesterol, mmol/L 3.39 ± 0.96 3.52 ± 1.02 3.83 ± 0.97 <0.0001 
Uric Acid, µmol/L 
320 (273, 
369) 
310 (263, 
357) 
298 (253, 
352) 
<0.0001 
hs-CRP, mg/L 
2.14 (0.89, 
3.90) 
1.77 (0.76, 
3.53) 
1.55 (0.62, 
3.12) 
<0.0001 
Blood glucose, mmol/L 6.26 ± 1.82 5.9 ± 1.64 5.43 ± 1.15 <0.0001 
84 
 
Figure 3. MLDP score adherence and latitude 
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Figure 4 shows that the risk of event in subject consuming items present in a 
MLDP was lower than the risk of those in whom the consumption threshold was 
not reached. This is especially clear for those consuming fish >2 times/week whose 
risk of event was 39% lower than that of the ones that consumed fish < 2 
times/week; a similar risk reduction was found in those consuming meat <2 
times/week (that have a 34% risk reduction) compared to than those that 
consume meat > 2 times/week.  
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Figure 4 Single items of an MLDP t and the risk of events 
 
 
At multivariable analysis (Table 3), latitude was the strongest (r2=0.1768) 
independent determinant of MLDP score. Social and behavior variables such as 
BMI; smoke; pulse pressure; Hs-CRP; creatinine; education (expressed as study 
years); occupation; physical activity; HDL-cholesterol; use of antiplatelet agents; 
insulin treatment and statin treatment were also significantly associated. By 
contrast, sex, age, blood glucose, triglycerides, uric acid, white blood cell (WBC) 
count, family history of PAD, CVD and CAD and pharmacological treatments (β-
blockers, calcium antagonists, ACE inhibitors, ARB, diuretics, insulin, oestrogens, 
statin, fibrates and fish-oil) were not significantly associated to MLDP score.  
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Table 3. Variables independently associated with Mediterranean-like dietary 
pattern (MLDP) score by multivariable linear regression with stepwise selection. 
 
*β values indicate changes in MLDP score associated with a unit increment in the predictor. 
Variables not significantly associated were: sex, age, blood glucose, triglycerides, uric acid, WBC 
count, family history of PAD, CAD and CAD and other pharmacological treatments (β-blockers, 
calcium antagonists, ACE inhibitors, ARB, diuretics, insulin, estrogens, fibrates and fish-oil). 
  
Variables Beta* SE P value Partial r2 
Latitude (degrees) -0.09 0.003 <0.0001 0.1768 
Education (study years) 0.03 0.01 <0.0001 0.0074 
Use of antiplatelet agents 0.19 0.06 0.0007 0.0050 
Physical activity (1 step) 0.11 0.03 0.0003 0.0038 
Log Hs-CRP (mg/L) -0.14 0.04 0.0009 0.0036 
Pack-years of cigarettes  -0.003 0.001 0.009 0.0034 
HDL-cholesterol (mmol/L) 0.20 0.06 0.002 0.0033 
Creatinine (µmol/L) -0.003 0.001 0.02 0.0024 
Body mass index (Kg/m2) -0.02 0.01 0.002 0.0022 
Insulin treatment -0.25 0.11 0.03 0.0020 
Pulse pressure (mmHg) -0.004 0.002 0.02 0.0020 
Statin treatment 0.12 0.04 0.006 0.0019 
Occupation (office work) 0.10 0.05 0.03 0.0015 
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When the variables independently associated with MLDP were evaluated as 
related to each center, a significant positive correlation between MLDP and 
education, as indexed by study years, was observed in Paris p=0.04; Groningen 
p=0.03; Stockholm p<0.0001; Kuopio p<0.0001 Centers,) but not in Italian Centers. 
Validation analysis (MLDP score vs VEs) 
Before testing the MLDP adherence score versus the primary endpoint (i.e. the 
association with c-IMT-progression), whether MLDP score was associated with VEs 
was analyzed. Among the 3,703 subjects enrolled in the IMPROVE Study, 215 
(7.96%) developed a first VE within the 36-month follow-up. Of the VEs, 32 were 
hard ischemic strokes and 37 were hard coronary events. Number of events 
according to MLDP score classes are in Table 4.  
 
Table 4. Vascular events stratified according to the Mediterranean-like dietary 
pattern (MLDP) score. 
 
  
Table 3 shows that latitude was the strongest independent determinant of MLDP 
score, accounting for approximately 83% of the variation explained by the 
regression model (p<0.0001). 
 
Figure 5 panel A shows the Kaplan-Meier incidence curves of the combined end-
point stratified by MLDP score classes. The rate of events was highest in subjects 
with score 0-1; lower in those with score 2-3 and lowest in those with score 4-7.  
 
  
Type of events MLDP Score 
 0-1 n (%) 2-3 n (%) 4-7 n (%) 
Total Events (cardio+ cerebro  
+ peripheral vascular events) 
101 (9.2) 
94  
(5) 
20 (2.7) 
    
Hard cerebrovascular events (ischemic stroke) 19 (1.7) 12 (0.6) 1 (0.1) 
Hard coronary events (AMI + sudden cardiac 
death) 
15 (1.4) 17 (0.9) 5 (0.7) 
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Figure 5. Association of the IMPROVE MLDP score with CV events (composite end-
point). Kaplan Meier event-free survival curves.  
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When hard coronary and hard cerebrovascular events were analyzed separately, 
the protective effect of MLDP was stronger with respect to cerebrovascular than 
to coronary endpoints (Figure 5, Panel B and C). Being the association with VEs 
highly significant, MLDP adherence score was considered as being validated and, 
as such, suitable for the assessment of its association with c-IMT change over 
time. 
MLDP score and c-IMT 
In an unadjusted model, MLDP was significantly associated with baseline c-IMT 
variables. The associations, however, disappeared when smoking, physical activity, 
education, occupation, and CV risk factors (BMI, heart rate, lipids, glucose, 
creatinine, uric acid, CRP) were included into the model (Table 5).  
Table 6 shows the mean (±SD) values of c-IMT progression variables stratified by 
MLDP score categories and association between MLDP score and c-IMT 
progressions by unadjusted (Model 1) or adjusted (Models 2-3) linear regression 
models. A significant negative trend was found between MLDP score and most of 
c-IMT-progression variables, regardless of adjustment for all potential 
confounders (Table 6, Models 1-3). 
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Table 5 Association between MLDP score and baseline carotid C- IMT by multivariable unadjusted or adjusted linear regression models§*. 
 
§. Definitions of such variables and their abbreviations are reported in the Additional material of this study. 
Model 1: unadjusted; Model 2: adjusted for age, sex, latitude; Model 3: as model 2 plus smoking, body mass index, education, physical activity, occupation, lipids 
(LDL and HDL cholesterol and triglycerides), Hs-CRP, creatinine, plasma glucose, pulse pressure. 
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Table 6. Progression of ultrasonographic variables according to classes of Mediterranean-like dietary pattern (MLDP) score (column 3) 
and association between MLDP Score and carotid artery intima media thickness (c-IMT) progression by multivariable unadjusted or 
adjusted linear regression models (Models 1-3). 
 
Model 1: unadjusted; Model 2: adjusted for age, sex, latitude; Model 3: as model 2 plus pack-years, body mass index, education, physical activity, occupation, lipids 
(LDL and HDL cholesterol and triglycerides), plasma glucose, high sensitive C-Reactive Protein, creatinine, pulse pressure, antiplatelet,
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A significant association was also found between MLDP score and c-IMT 
progression variables (Figure 5; Figure 6, and Table 7) Accordingly, when plotted 
vs the MLDP score, progression of IMTmean-max was nearly 2-fold lower in those 
with MLDP scores 4-5 than in those with MD scores 0-1 (0.019 vs. 0.035 mm/yr, 
Ptrend=0.01). No association was found between MLDP score and baseline c-IMT 
(Figure 6). The significant association between MLDP score and Fastest-IMTmax-progr 
is shown in Figure 7. 
 
Figure 5. Carotid IMT and IMT progression according to MLDP score. 
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Figure 6. MLDP and IMT in the IMPROVE Study  
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Table 7. Association between MLDP and C-IMT progressions by multivariable unadjusted or adjusted linear regression models.
Model 1: unadjusted; Model 2: adjusted for age, sex, latitude; Model 3: as model 2 plus smoking, body mass index, education, physical activity, occupation, lipids 
(LDL and HDL cholesterol and triglycerides), Hs-CRP, creatinine, plasma glucose, pulse pressure. 
Model 4: model 4+baseline fastest+ fastest.
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Figure 7. Association between MLDP and Fastest-IMTmax-progr 
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MLDP score and indices of inflammation. 
There was a significant negative correlation between hs-CRP and MLDP adherence 
when correcting these results for confounders (age, gender, latitude) the results 
were further confirmed (r= -0.034; p<0.0001). (Figure 8). 
 
Figure 8. Effect of MLDP on hs-CRP  
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A significant negative correlation was observed when analyzing WBC and MLDP 
adherence and correcting these results for confounders (age, gender, latitude) 
(Figure 9). 
 
Figure 9. Effect of MLDP on WBC  
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The RISMED Study 
Characteristics according to diet of 52 patients (ongoing analysis) (28 LFD and 24 
MD) so far analyzed are detailed in Table 8. Mean age was 61.3 years for MD 
group and 62.8 for LFD. Moreover, 83.3% of subjects in the MD group were males 
whereas males 89.5% in the LFD. 
No difference was found by comparing the two groups as stratified according to 
the parameters listed above. 
Table 8. Baseline characteristics of participants 
  
100 
 
Correlation between inflammatory markers and MD adherence 
A significant negative correlation between MD delta score adherence and hs-CRP 
was found (r= -0.40778; p=0.0027) following 3-mo of diet (Figure 10). An inverse 
no significant correlation of WBC with MD delta score adherence (r= -0.03; p=0.84) 
was also documented.  
 
Figure 10. Correlation between hs-PCR and MD score adherence 
 
MD and FAs profile 
Several components of the blood fatty acid profile differed between cases and 
controls (Figure 11) following a 3-mo of dietary intervention. MD patients had 
significantly lower C16:0 (Palmitic acid) content as compared to LFD patients. Total 
monounsaturated fatty acid (MUFA) and C18:1 (oleic acid) were similar in both 
groups, whereas C16:1 (palmitoleic acid) and C20:1 were higher in MD group than 
in LFD group. MD also had higher total PUFA-n-6, C20:3n-6 (dihomo-γ-linolenic 
acid DHLA), C20:4n-6 (arachidonic acid), C22:4n-6, C22:5n-6 (docosapentaenoic 
acid) than controls. In addition, there were also higher total PUFA-n-3, C22:5n-3 
(DPA) and C22:6n-3 (DHA) in patients that followed an MD as compared to LFD 
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controls. Figure 11 also shows differences between groups in FA ratios, MD diet 
showing higher n-3 fatty acids compared to LFD. Moreover, there was a lower n-
6/n-3 ratio in patients that received an MD than in controls. Likewise, positive 
significant correlations between MD adherence score and C20:1 (r=0.36; p=0.03); 
C20:3n-6 (dihomo-γ-linolenic acid DHGLA) (r=0.33; p=0.05); C20:4n-6 (arachidonic 
acid) (r=0.46; p=0.005); C22:6n-3 (DHA) (r=0.47; p=0.004), and n-3 fatty acids 
(r=0.36; p=0.03), were observed. Finally, a significant negative correlation was 
documented between MD adherence score and C16:0 (Palmitic acid) and n-6/n-3 
ratio (r=-0.36; p=0.03). 
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Figure 11. Fatty acid profile in cases and controls after 3-mo diet 
 
*p value ≤ 0.05  
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MD and Oxidative stress status  
When analyzed together, the MD group and the LFD group had a significant 
reduction of GSSG/GSH ratio (p=0.005) 3 months after a healthier diet pattern. In 
parallel, the MD group and the LFD group had a similar weight loss (MD -3.20; C.I. 
95% -4.49, -1.92 p<0.001; LFD -3.34; C.I. 95% -4.53, -2.16 p<0.001) and a similar 
waist circumference reduction (MD -3.96; C.I. 95% -5.17, -2.74 p<0.001; LFD -3.61; 
C.I. 95% -4.87, -2.34 p<0.001) at completion of the 3-mo healthier dietary 
patterns. However, when splitting the results based on the different diet followed 
by the patients, only those that followed a MD dietary pattern had a reduction in 
the oxidative stress status (p=0.016) (Figure 12).  
also 
Figure 12. GSSG/GSH ratio in cases and controls after 3-mo diet 
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Correlation between oxidative stress and single items of the MD 
A significant negative correlation between GSSG/GSH ratio (Figure 13) and the 
quantity of legumes consumed in the MD diet (r=-0.33; p=0.03) was found.  
 
Figure 13. Correlation between GSSG/GSH ratio and legumes consumption 
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Correlation between oxidative stress and FAs profile  
A significant negative correlation between GSSG/GSH ratio (Figure 14) and the 
alfa-linolenic acid ALA (C18:3n-3) (r=-0.43; p=0.01) content was found. Consistent 
with the antioxidant activity of PUFA, a significant positive correlation between 
GSSG/GSH ratio (Figure 15) and n-6/n-3 ratio (r=0.38; p=0.02) was found. 
 
Figure 14. Correlation between GSSG/GSH ratio and alfa-linolenic acid  
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Figure 15. Correlation between GSSG/GSH ratio and n-6/n-3
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Discussion 
In this new analysis of the IMPROVE Study we have shown that, by using a non-
invasive ultra-sonographic diagnostic technique, that allows the assessment of c-
IMT changes over time, it is possible to detect the effect of a specific diet in a 
relatively short time (15 months). The dietary pattern considered was the 
Mediterranean diet, which was measured by using a relatively simple food 
frequency questionnaire (Mediterranean-like dietary pattern adherence score - 
MLDP-) validated a priori vs VEs. In addition, in this new analysis of the IMPROVE 
Study we have also shown the involvement of the inflammatory pattern, 
documenting that MLDP is associated to hs-CRP and, in North Europe only, with 
white blood cells. Such relationship is in keeping with data stemming from the 
second part of this thesis (the RISMED Study) which show: 1) that by consuming a 
MD it is possible to modify favorably the plasma fatty acid (FA) profile known to be 
altered in patients with CAD; 2) that blood FA profile is an index of the quality of 
food intake which might be used as a tool to estimate diet quality and compliance 
with nutritional advices; 3) that MD is able to affect some indices of inflammation 
and oxidative balance; and 4) that there is a relationship between these 
inflammatory/oxidative changes and the modification of the blood FA pattern.  
 
MLDP adherence and c-IMT or c-IMT change over time. 
The IMPROVE is the unique observational study that, besides the associations 
between MLDP and cross-sectional c-IMT, evaluated also the association with c-
IMT progression. This association was best detected by using the Fastest IMTmax-
progr, the unique carotid IMT progression variable that previous data of the 
IMPROVE study have shown to be strongly associated to VEs. 249 In addition, we 
have shown that these associations were stronger in carotid segments with the 
highest atherosclerotic involvement, i.e. carotid bifurcations, suggesting a stronger 
impact of MLDP on focal atherosclerosis rather than generalized thickening of the 
vessel wall. 250 Taken together, these data support the usefulness of carotid 
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atherosclerosis change over time as a surrogate endpoint to assess the effects of 
dietary interventions in epidemiological studies instead of baseline c-IMT 
measurements only. In fact, with c-IMT measured at baseline, we did not find any 
association with MLDP. The latter issue was previously investigated in three 
observational studies. 241, 250, 406 
In the first, a cross-sectional study from South of Italy carried out on 929 adults 
without known diabetes or atherosclerotic cardiovascular disease, no significant 
association was found between a dietary pattern similar to the one reported here 
and carotid atherosclerosis, defined as the presence of plaques and/or increased 
intima–media thickness.406  
 
The second, included 1,374 participants of the Northern Manhattan Study. 
Although no cross-sectional association between MLDP and c-IMT (or 
presence/absence of plaque) was found, a significant association with plaque size 
obtained comparing the top vs 1-3 quartiles of plaque thickness and comparing 
the plaque area above or below the median was found in regression analyses after 
controlling for confounders.250  
 
In the third one, a cross-sectional study carried out in 110 HIV-infected patients 
and 131 non-HIV-infected participants, a poor adherence to a MLDP score was 
associated in multivariable analysis with higher risk of subclinical atherosclerosis, 
indexed by both c-IMT≥0.9 mm and/or presence of at least one carotid plaque.241 
So, our results are in line with the results from Buscemi et al., 406 at least partially, 
with those from Gardener et al,250 but not with those of Viskovic et al. 241 
 
The lack of associations between MLDP and cross-sectional c-IMT after adjustment 
for confounders can be explained, considering that the one-time measured c-IMT 
reflects the complete burden of genetic and environmental factors acting 
throughout the entire life of the subjects, whereas carotid IMT change over time is 
mainly the response to VRFs and behaviors acting in relatively recent times. 
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Indeed, the food questionnaire we administered to our middle age population, 
likely reflected the diet followed in the last years, whereas no information was 
available about the life-long food behavior.  
 
Another issue that deserves to be highlighted concerns the relationship between 
MLDP and VEs in different European Countries. With one exception, 402 only 
single-nation studies have so far addressed the relation between MD scores and 
VEs (Greece, 24 USA,407 north Sweden408). However, rather than the association 
itself, the important information stemming from these new analyses from the 
IMPROVE Study lies on the fact that such association is independent of baseline c-
IMT and c-IMT progression. Such issue, never reported before, suggests that the 
protective effects of MD on VEs acts through mechanisms that are not directly 
related to the size and growth of atherosclerotic plaques, but to other 
mechanisms e.g. low-grade inflammation. In line with these considerations, 
several authors outlined the association between immune and inflammatory 
processes and the composition of gut microbiota 409 which, in turn, has been 
related to dietary habits, especially to MD.410, 411 Notably, Hs-CRP, a widely 
accepted marker of low grade inflammation, is an important (although not the 
only) mediator of the effect of MD on VEs 412. 
 
MLDP score adherence, vascular events and latitude. 
The simplified IMPROVE-Study MLDP score, included: fruits, fish, wine, olive oil, 
meat, milk and eggs. Despite such simplification, we have shown that the rate of 
events was highest in subjects with score 0-1; intermediate in those with score 2-3 
and low in those with score 4-7. This suggests that it is possible to gather 
information of the effect of a Mediterranean-type of diet on CV disease even 
considering few dietary items. The present results are in keeping with other 
reports in the area.  
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In the study performed by Estruch et al., the Authors observed that in subjects at 
high risk of cardiovascular disease, MD plus olive oil and MD plus nuts are able to 
reduce the incidence of major cardiovascular events.413 
 
With the exception of the EPIC-Netherlands cohort,414 the concept of high 
consumption of eggs, meat, and fried foods and high risk of acute VEs is true in 52 
countries in the INTERHEART study;415 in the US population,416-419 and in China.420 
On the other hand, at variance with the results of some,415, 417-423 but not all 
studies, 424, 425 a low risk of developing CAD is seen with the use of plant-based 
nutritional patterns (as in the REGARDS Study).426-428  
 
Despite European countries have increasingly similar patterns of food availability, 
likely due to the invading fast-food culture that has spread dramatically in the 
Mediterranean area,429 the new information raised from the IMPROVE study 
results documents that the rate of VEs across the 5 European countries involved in 
the study vary along a north to south geographical gradient and correlate 
significantly with the intake of major components of the MD food, with a greater 
adherence to the MLDP score being associated with a lower likelihood of having 
VEs. 
We have also shown that the association between VEs and the MLDP score is 
stronger in North than in South European Countries, independently of 
anthropometric, lifestyle and other clinical characteristics. 
Of note, also the association between MLDP score and the level of education is 
stronger in northern than in southern countries, thus confirming the results of 
Regmi et al.,430 which showed that the income and the economic environment 
may have a crucial role in the context of the dietary pattern. One of the possible 
explanations is that while the items of MD diet are easily available to everybody 
and relatively cheap in the south of Europe, they are more expensive in northern 
countries and, as such, they are available only to the highest socio-economic 
classes. 247, 431-433 An alternative explanation might be the differences between 
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Mediterranean and non-Mediterranean countries in terms of socio-demographic, 
anthropometric and lifestyle factors. For example, a low socioeconomic 
environment has been associated with high stroke mortality in cohort studies434, 
435 and in studies investigating the geographic distribution of stroke.436, 437  
 
The issue of different nutritional patterns in Europe has been previously analyzed.  
A large variability in nutrient intake across European populations with a 
geographical gradient within and between European countries has been 
described.438 Three main region-specific patterns have been identified. In 
Mediterranean regions, including Greece, Italy, and the Southern of Spain, the 
nutrient patterns are mainly governed by a relatively high intakes of vitamin E and 
MUFA, whereas retinol and vitamin D intakes are relatively low. The general 
population in Germany, in the Netherlands and in the UK share relatively high 
intakes of PUFA and saturated fatty acids, and relatively low intakes of MUFA, in 
combination with a relatively high intake of sugar. These differences are justified 
by a diet rich in plant foods and olive oil in Greece, Italy and, to some extent, also 
in Spain.439, 440 By contrast, the diet in the general population of northern 
countries (Germany, the Netherlands, and UK) is characterized by a higher 
consumption of animal, processed, and sweetened foods -including nonalcoholic 
beverages and soft drinks-, and, more specifically, added fats and dairy products, 
which are often fortified with retinol and vitamin D.439-442 Margarine and 
processed meat are the main food sources of PUFA in Germany and the 
Netherlands.443 Recently, a general north-south gradient for the contribution of 
highly industrially processed foods to overall food consumption in Europe has 
been shown.444  
 
MD and inflammation  
As far as the relationship between MD and inflammation is concerned, the 
absence of correlation between MLDP score adherence and WBC and the 
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significant negative correlation with hs-CRP (Figure 8 and Figure 9) were 
documented in the IMPROVE study and confirmed in the RISMED Study.  
 
These results, which suggest an involvement of the anti-inflammatory effect of 
MD, corroborate several previously reported data. For example, in  the study of 
Jiang et al it was shown that a frequent intake of nuts is associated with decreased 
levels of IL-6, C-reactive protein, and fibrinogen in a population free of CAD.445 
Similarly, the study of Dell’Agli et al., showed that olive oil down-regulates 
vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and E-selectin 
expression in the endothelium,446 and decreases plasma levels of soluble 
intercellular adhesion molecule-1; soluble E-selectin; IL-6, and hs-CRP, in high-risk 
patients;447-449 all widely accepted markers of inflammation. 
MD supplemented with walnuts also decreases the level of soluble vascular cell 
adhesion molecule-1 in healthy subjects and in patients with 
hypercholesterolemia.450 Moreover, two cross-sectional studies451, 452 and a 
feeding trial in Mediterranean populations 357 further support the concept that 
MD exerts anti-inflammatory effects.453  
 
The involvement of inflammation in such contest is also by an interventional study 
(the pilot study of the PREDIMED trial) in which the effects of the three dietary 
interventions (MD plus olive oil, MD plus nuts and low-fat diet) modify the 
expression of soluble adhesion molecules and cytokines related to 
atherosclerosis.308 Such concept was previously suggested by studies showing that 
MD -or its components- are associated with a lower inflammatory status and/or 
an improved endothelial function.24, 358, 402, 450, 454 Similar findings have been 
obtained by considering other healthy dietary patterns.358  
 
In a sub-analysis carried out in a high-CAD-risk group of the PREDIMED population, 
it has been addressed also the role of immune cell activation and of soluble 
inflammatory biomarkers.455 The authors observed, after 3 months of the 
113 
 
aforementioned three-dietary interventions, that the expression of CD49d (an 
adhesion molecule crucial for leucocyte homing), and of CD40 (a pro-inflammatory 
ligand) decreased in the MD plus olive oil group, in the MD plus nuts group but not 
in the low-fat diet group. In the two MD groups, a reduction in serum IL-6 and in 
the soluble intercellular adhesion molecule-1 was also observed while both these 
soluble markers resulted to be increased in the low-fat diet group. On the other 
hand, CRP decreased only in the MD plus olive oil group. This inhibition of both 
cell-mediated and humoral inflammatory pathways can be viewed as a possible 
molecular mechanism for the anti-atherosclerotic effect of the MD.  
 
In both the IMPROVE and the RISMED Study, the beneficial effects of MD on 
inflammatory markers were comparable both considering the subjects treated 
with risk-reducing agents known to have anti-inflammatory properties (e.g. statins 
and angiotensin-converting enzyme inhibitors), and those not treated with such 
drugs. This suggests that the anti-inflammatory effect of MD is complementary to 
that provided by potentially anti-inflammatory pharmacological treatments.  
 
The benefit of dietary change in the IMPROVE and in the RISMED Study occurred 
regardless of patients’ age. This suggests that the anti-atherosclerotic effects of 
healthy foods are not limited to a specific phase of the disease (earlier or overt) 
and supports the recommendation that the MD is a tool potentially useful against 
CAD in all its stages. 456 Similar findings have been described by Estruch in a 
commentary of the PREDIMED study.456 In such commentary, the author 
concluded that the adherence to MD might be considered as a health tool even in 
elderly patients at high risk of cardiovascular diseases.  
 
MD and Oxidative stress  
As to the inverse association between adherence to MD and oxidative stress here 
reported, we believe that this result is relevant in view of the lack of randomized 
controlled trials assessing the effects of MD on glutathione redox pathways in the 
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general population. Our result is in keeping with data from animal experiments 
showing that polyphenols naturally present in Mediterranean foods decrease the 
GSSG/GSH ratio and GSSG concentrations without changing GSH 
concentrations.457, 458  
One possible explanation of the GSSG/GSH ratio reduction can be found in the 
diverse nutrients present in a typical MD that can provide NADPH459 (oxidized by 
gluthathione reductase to revert GSSG to GSH). 460 
 
A “sparing effect” on the GSH/GSSG redox cycle may indeed contribute to an 
increased GSH/GSSG. By providing additional antioxidants (e.g. vitamin C, vitamin 
E, carotenoids, polyphenols, zinc, selenium) and ensuring adequate activity and 
efficiency of antioxidant enzymes, 373 MD may decrease the need for the 
GSH/GSSG antioxidant pathway, which may “spare” the GSH/GSSG recycle.461  
 
As in the RISMED Study, several reports have addressed the possibility of an 
(inverse) association between MD adherence and oxidative stress. However, the 
results were not entirely consistent.  
 
A few small trials462-465 and one large trial385, examined short- or intermediate-
term effects of MD on other circulating markers of oxidative stress, including 
urinary F2-isoprostanes463, plasma malondialdehyde464, and oxidized LDL.385, 458, 462, 
465 In the largest of these trials, subjects assigned to MD had lower oxidized LDL 
than did those following the control diet.385 Other trials, however, yielded 
different results.  
 
This inconsistency might be due to the different biomarkers measured. Individual 
markers may signal different metabolic pathways, 369 and it is conceivable that 
only some pathways are influenced by diet. The possibility of unmeasured 
confounding related to different genetic backgrounds and familial factors should 
also be considered. 
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MD and FAs profile 
Concerning variations of blood fatty acids, our results are in line with those from a 
study on 1,050 French elderly community dweller from Bordeaux (mean age 75·9 
years), in whom MD adherence (scored as 0–9) was computed from a FFQ and 24 
hours recall.395 As in our study, after adjusting for several personal and 
environmental variables, plasma DHA, the EPA+DHA index and total n-3 PUFA 
were positively associated with MD adherence. At variance from our study, 
however, plasma palmitoleic acid was significantly inversely associated with MD 
adherence, and the n-6:n-3 PUFA, AA:EPA, AA:DHA and AA:(EPA+DHA) ratios were 
inversely associated with MD adherence. Similarities and differences between 
these two studies are now under intensive investigation in our laboratory. The 
possibility that higher than expected palmitoleic acid levels might be due to an 
enhanced conversion of palmitic acid in subjects receiving a MD has been recently 
proposed by our group.396 
 
Moreover, the lower palmitic acid content observed in our study, is in line with 
that observed in the study by Shearer et al.,356 that pbserved that blood levels of 
palmitic acid are strongly associated with CAD. 
 
As to the negative correlation between GSSG/GSH and α-linolenic acid (C18:3n-3) 
levels, and the simultaneous positive correlation between GSSG/GSH ratio and n-
6/n-3 ratio, our data are in keeping with animal studies. A reduced hepatic lipid 
content, and a concomitant reduction in antioxidant response with higher 
GSSG/GSH ratio and reduction of indices of inflammation (i.e. serum tumor 
necrosis factor-α, IL-1β, and IL-6 levels) occurs following dietary supplementation 
of PUFA in obese male C57BL/6J mice fed a high fat diet.466  
 
All in all, the relationship between oxidative changes and blood FA pattern 
modifications that emerges from the ongoing results of the RISMED argues for a 
direction to be pursued to identify mechanisms of the protective effect of MD.  
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Limitations 
The two studies analyzed here (and the combined discussion of their results) have 
some potential limitations: 1) being both observational studies, no causal relation 
can be demonstrated between MD and clinical or subclinical disease; 2) although a 
variety of potential confounders have been taken into account, a residual 
confounding effect of unmeasured factors cannot be ruled out; 3) the IMPROVE 
study has been carried out in different Countries whereas the RISMED Study has 
only taken into account Italian individuals; 4) at variance with the RISMED Study, 
in the IMPROVE Study diet was assessed only at the beginning of the study and 
dietary changes occurring later may have led to non-differential misclassification 
and underestimation of the true associations; 4) in both cases the dietary 
assessment was based on a food frequency questionnaire much simpler than that 
employed in other studies (e.g. the EPIC questionnaire24), and 5) pre-vs post 
analyses of the only RISMED Study have been carried out after only a 3-mo 
intensively advised MD in Mediterranean males and females with a recent history 
of coronary revascularization. However, the strength and the consistency of the 
data presented here suggest that the beneficial effect of an MD nutritional pattern 
can be easily extrapolated using a limited number of food items, and that its 
association with VEs is so strong to be detectable even in the presence of a certain 
degree of misclassification, including time of exposure to MD. In addition, the 
Italian population examined in the RISMED Study is superimposable to the Italian 
population evaluated in the IMPROVE Study. Furthermore, as in previous reports 
in the area, 450 in both studies, the beneficial effect of MD on inflammatory 
markers was comparable in subjects under stable treatment with agents that have 
demonstrable anti-inflammatory properties, -e.g. angiotensin- converting enzyme 
inhibitors and statins-, and in those not treated with these drugs, suggesting that 
the anti-inflammatory effect of the MD is in both cases complementary to that of 
the pharmacological treatment. 
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Conclusions 
Using a non-invasive ultrasonographic diagnostic technique to assess c-IMT 
changes over time, it is possible to detect the effect of a specific diet in a relatively 
short time (15 months), in this new analysis of the IMPROVE Study. In addition, by 
using a relatively simple food frequency questionnaire (MLPD score), validated a 
priori vs VEs in different European Countries, we have found that: 1) the significant 
association between MLDP adherence and VEs is independent of baseline c-IMT 
and c-IMT progression; 2) regardless of adjustment for potential confounders, a 
significant negative trend exists between MLDP score and most of c-IMT-
progression variables (but not baseline c-IMT variables); 3) MLDP adherence is 
associated to both hs-CRP and white blood cells, the latter having a north to south 
gradient with stronger association in northern countries; 4) the latter relationship 
is in keeping with data stemming from the RISMED Study (showing that MD 
adherence may affect some indices of inflammation and the oxidative stress 
balance); 5) blood FA profile in the RISMED Study is an index of the quality of food 
intake which might be used as a tool to estimate diet quality and compliance with 
nutritional advices; 6) by consuming a MD it is possible to modify favorably the 
plasma FA profile known to be altered in patients with CAD, and 7) there is a 
relationship between inflammatory/oxidative changes and the modification of the 
blood FA pattern that occur adhering to a MD.  
 
To test the diet heart concept, Ancel Keys organized a pilot study in 1957 in 
Nicotera, Calabria, where CAD was almost non-existent. Keys and his wife 
Margaret were highly impressed by the eating patterns of that and other 
Mediterranean cohorts, and decided to write, in the late ‘50s of the last Century, 
the book that became a best seller, "Eat Well and Stay Well" where great merit is 
given to MD for longevity.467, 468 Common approaches that target multiple risk 
factors, are expected to improve the probability of a better health at older ages.469 
Reduced oxidative damage has been documented in calories-restricted, longer-
surviving rodents. 470 Reduced oxidative stress and inflammation, and control of 
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body weight are important effects of MD. Thus, MD has the potential to be 
considered to prolong a healthy life in man.24 , 339, 402, 471  
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